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ABSTRACT 
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL 
ESTRADIOL-TRIAZOLE ANALOGS TARGETING EPIDERMAL GROWTH 
FACTOR RECEPTORS IN COLORECTAL CANCER 
                            FAEZ ALOTAIBI 
2017 
Colorectal cancer is a life threatening and second cause of death from cancer in the United 
States. Several proteins (molecular targets) are highly expressed in Colorectal cancer 
(CRC). Among these molecular targets is Epidermal Growth Factor Receptors (EGFRs) 
which are overexpressed in cancer cells. Targeting and blocking the downstream signaling 
could lead to cease cell proliferation and division and hence control the spread of the 
disease. Molecular modeling is a powerful tool in drug discovery, which has been utilized 
to design many drug candidates that exhibit biological effect in many disease including 
cancer. Additionally, pharmacophores such as 1,2,3-triazole showed potency towards 
many diseases including cancer. Therefore, incorporation of 1,2,3-triazole on a carrier such 
as estradiol could lead to novel analogs in drug discovery for treatment of cancer. A library 
of 800 compound containing 1,2,3-triazole-estradiol analogs were designed and virtually 
screened with seven molecular targets belong to EGFRs utilizing OpenEye® software. 
Among the designed candidates, fourteen of estradiol-triazole analogs were synthesized 
and biologically evaluated. Antiproliferation/cytotoxicity assay conducted on CRC cancer 
cell line (HT-29) showed that 5 out 14 analogs demonstrated potential antiproliferation 
activities ranging from 3.5 µM to 30 µM in comparison to a chemotherapeutic agent 5-
flurouracil (5-FU) (IC50 17.3 µM) which is a standard drug for CRC. 
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CHAPTER ONE 
General Introduction and Background 
 
1.1. Natural Products as a Drug Discovery Tool 
Humans rely on natural sources for many purposes, such as energy sources, food 
and medicine. Particularly the natural sources for medicines had the greatest impact on 
humans lives and prosperity. Therefore, it kept the interest of humans growing and 
evolving until it has shaped a massive industry known today as pharmaceuticals. At the 
early ages of pharmaceutical companies, it was the standard procedure to use the crude 
extract to generate relatively crude therapeutic formulations until the mid-twentieth century 
when the separation techniques were developed and became of great help for purification 
of extracts [1-3]. In the realm of cancer and infections it is estimated that 60% and70% 
respectively of the drugs discovered and marketed are isolated from natural sources.  
The natural sources of drugs varies from plants, microorganisms, and animals, 
among of which the marine natural products, can be marine plants, microorganisms or 
animals, became the trend of drug discovery as the products isolated usually have 
enormous diversity and multiple functionality in addition to complexity. Natural products 
normally carry a group of atoms that are responsible of biological activity, this group of 
atoms called pharmacophores. Pharmacophores can react with molecular targets, such as 
receptors, utilizing multiple interactions and forces and hence cause certain biological 
response. Therefore, pharmacophores have been used as fingerprints for certain proteins 
utilizing qualitative and quantitative structure activity relationships as well as virtual 
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screening [4]. For example, one technique becoming popular in drug design is modeling of 
pharmacophore-based ligands with molecular targets under investigation to identify hits 
compounds that can be later optimized to become drug candidate. This technique is called 
ligand-based pharmacophore modeling [5]. Furthermore, pharmacophores significance can 
also be observed in another modeling technique, which called structure-based 
pharmacophore modeling, in which the modeling process deals with the 3D structure of 
the molecular target under investigation and/or the 3D structure of the molecular target 
complex with the ligand. This technique can map the interactions with the macromolecule 
and express these interactions as number of  hydrogen bond acceptors, donors and 
hydrophobic interaction with the binding site of the macromolecule [4, 5]. To illustrate 
more, a pioneer study conducted by Zou et al., have established a map of all of the 
important interactions between Cyclin-dependent kinase CDK,  a highly expressed protein 
in cancer,  and 124 inhibitors and hence established a comprehensive  pharmacophore for 
their  CDK macromolecules under investigation [6]. 
  To sum it up, natural products pharmacophores became successful trend in drug 
discovery and contributed with tremendous effort toward the progress of the 
pharmacophore modeling techniques as well as  chemoinformatics, which made it a 
powerful tool in drug discovery approaches today[5, 7].  
1.2.  Click Chemistry as a New Tool in Organic Synthesis 
In 2001 K.B Sharpless reported a class of reactions that are rapid, wide in scope, easy 
to preform and high yielding. These reaction was named later as “ click chemistry 
reactions” and the demanding pharmaceutical industry has triggered the grow of this class 
of reactions in a way that allow synthetic chemist to synthesize a library of compounds and 
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screen them on a macromolecule of interest as a reliable method for drug discovery.  
Although click chemistry can describe many reactions including nucleophilic ring opening, 
formation of heterocyclic compounds and hydrazones from ketones and reaction of 
aziridine and epoxides; however, thermal cycloaddition, especially Huisgen 1,3 dipolar 
reactions, have been widely investigated in click chemistry [8].  
   Huisgen reaction is classified as cycloaddition reaction that occur between 
a 1,3-dipolar and dipolarphile Scheme 1.1. The result of this reaction is a five-membered 
heterocyclic ring. In this reaction, there is a critical need for elevated temperature for the 
reaction to occur and the resulting compound lack regioselectivity [8].  
R1 R N3+
N
N
NR
R1
1 2
3
45
N
N
NR
1 2
3
45
+
R1
 
Scheme 1.1. Huisgen 1,3-dipolar reaction lacks selectivity. 
The lack of regioselectivity indicates that the reaction has different mechanism 
pathways that result in different products. To control the regioselectivity, K. B. Sharpless 
reported optimized conditions, most importantly, the catalyst in use significantly affect the 
product obtained from the cycloaddition. To illustrate more, the use of copper sulfate 
(CuSO4) or copper sulfate pentahydrate (CuSO4.5H2O) can direct the reaction to the 
pathway that result in 1,4-regioselectivity. On the other hand, ruthenium catalyzed click 
reactions direct the azide-alkyne cycloaddition to the 1,5-regioselectivity. Below scheme 
1.2 explains how the 1,3-dipolar cycloaddition became selective and efficient based on the 
condition used. 
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R1 R N3+
N
N
NR
R1
1 2
3
45
Cu(I) (cat.)
H2O
 
R1 R N3+ N N
NR
1 2
3
45
Cp*RuCl(PPh3)(cat.)
Dioxan,
R1  
Scheme 1.2.The azide-alkyen cycloaddition exhibits regioselectivity based on the 
catalyst. 
Besides the catalyst, the solvent in use gave the click chemistry a great advantage. 
Click reactions can be performed in a media of water in addition to an organic solvent in 
different ratio. In addition to the reaction conditions, in case of Cu2+ is used as a catalyst, a 
reducing agent must be used to allow copper to catalyze the reaction. In other words, the 
reducing agent convert Cu2+ to Cu+, a necessary species to catalyzed the reaction. Click 
chemistry reactions are varies now in conditions since the outstanding efforts of K. B. 
Sharpless.  
1.2.1. Mechanism of Azide-Alkyne Cycloaddition Utilizing Copper as a Catalyst 
In contrast to 1,3-dipolar cycloaddition, utilizing click chemistry reaction 
conditions, especially the catalyst, can accelerate the rate of the azide-alkyne cycloaddition 
[9]. The rate accelerated is measured in 107 to 108 unites. In addition, utilizing these 
conditions can tolerate many functional groups, wide range of pH and aqueous media. 
Evidence obtained from real-time monitoring of the cycloaddition between azide and 
alkyne utilizing heat-flow reaction calorimetry explicitly indicate that monomeric copper 
acetylide complexes does not appear to be reactive toward organic azides unless an 
exogenous copper in a catalyst form is added. Moreover, isotopically enriched exogenous 
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copper source experiments showed that the carbon–nitrogen bond-formation has a stepwise 
nature and the equivalence of the two copper atoms must be obtained to pursue the 
cycloaddition steps [9, 10]. Kinetic studies conducted by Fokin et al.,2013 show that the 
pKa of alkyne is lowered in the process of the alkyne coordination by 10 folds, which 
explains the deprotonation of the alkyne-CuI intermediate without using any base but water 
itself, in aqueous medium conditions. [8, 9]. In addition, kinetic studies also indicate that 
the rate of the reaction is second order in presence of CuI even at low concentration and 
formation of less reactive copper aggregates at higher concentrations [10].  
The mechanism of the cycloaddition starts from the catalyst Cu+ which can be 
generated from Cu2+ salts using sodium ascorbate as reducing reagent, Cu+ can be used 
directly, once Cu+ is generated, a σ-bond copper acetylide is formed, and a π-bound copper 
to the azide moiety is formed as well [9, 10]. Consequently, an metallacycle constructed of 
six membered ring is formed. This step brings the azide and the alkyne together utilizing 
one copper atom and the π-bounded copper acts as stabilizing donor ligand. The following 
step is crucial as the aromaticity of triazolyl ring begins to form, triggered by ring 
contraction. Finally, the catalytic cycle is closed by the protonolysis which achieves the 
final 1,4-substituted triazole, Scheme 1.3 explains in detail the mechanistic pathway of the 
1,4- regioselective click reaction utilizing Copper as a catalyst [10]. 
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Scheme 1.3. The mechanistic route for the synthesis of 1,4-disubstituted triazole.the 
mechanistic route for the synthesis of 1,4-disubstituted triazole. 
 
1.2.2. Mechanism of Azide-Alkyne Cycloaddition Utilizing Ruthenium as A Catalyst 
The presence of ruthenium as a catalyst has significant effect on the formation of 
triazole product. It is regioselective only to one form of isomer,1,5-substituted triazole, 
thus different pathway of the reaction mechanism must have been taken to offer this class 
of regioisomer. Studies suggest that first step of the mechanism of the reaction starts when 
the oxidative coupling between azide and alkyne occur to offer a six-membered ring where 
ruthenium is being placed next to the most electronegative carbon of the alkyne which 
allow the carbon to bond with the electrophilic nitrogen atom i.e. first nitrogen atom. 
followed by reductive elimination to form the desired regioselective product of triazole 
[10, 11]. Density functional theory (DFT) calculations suggest that the reductive 
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elimination step is the rate determining step of this mechanistic pathway. Scheme 1.4 
shows the mechanistic route for the synthesis of 1,5-disubstituted triazole [11]. 
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Scheme 1.4. The mechanism of 1,5-disubstituted utilizing ruthenium as a catalyst. 
 
 It is worth to point out that the catalyst in use has impact the course of the reaction, 
however the rest of the reaction conditions are wide in scope. 
1.3. Azide-Alkyne Cycloaddition Conditions 
1.3.1. Solvents 
The most remarkable feature of Copper Alkyne-Azide Cycloaddition CuAAC is 
the variety of solvents used in the reaction. The solvent conditions are numerous including, 
polar solvents such as alcohols, acetone, acetonitrile, dimethyl sulfoxide DMSO, and 
dimethyl formamide DMF, non-coordinating solvents such as dichloromethane, 
chloroform, toluene, weakly coordinating solvents such as dioxane, tetrahydrofuran THF 
and pyridine, and aqueous solvents including mixtures of water with an organic solvent 
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such as alcohols. It is worth to mention that DMF is the most optimal solvent for CuAAC 
reactions especially when the Cul is introduced as CuBr without any additional ligand, as 
DMF cannot coordinate with Cul, hence will not lead to slow reaction or inert reaction [12, 
13]. 
1.3.2. Catalyst 
A wide ranges of Copper compounds were tested as catalysts and pre-catalysts 
including Cu2+, Cu1+ and Cu0. In all cases Cu1+ must be generated to catalyze the CuAAC, 
if not began with, in addition, Cu1+ concentration must be in its highest to assist the progress 
of the reaction. Many pre-catalysts were used in the investigation of the catalyst of CuAAC, 
for example, Cu2+ salts were used and CuSO4 is the most popular form of Cu
2+. 
Furthermore, Cu1+ salts, commonly CuBr Or CuOAc, can be used directly in the reaction 
with amine ligand or a base to prevent the aerobic oxidation to Cu2+. Finally, Cu0 can be 
used as a pre-catalyst in form of powder, wire and nanoparticles [10, 11, 13]. 
1.3.3. Azide and Alkyne Substrate 
Generally, steroelectronic effects can significantly impact the rate of reactions; 
However, in CuAAC reactions, the effect can be generalized fairly in terms of azide and 
alkyne substrates, to illustrate, Matyjaszewski has reported the impacts of electronic and 
steric effects on the reaction rate and conclude that the fastest rate was observed when the 
azide substrate has electron-withdrawing groups and has a minimum steric hindrance, on 
the other hand,  alkynes with α-carbonyl group  was observed to have higher activity than 
alkynes with alkyl groups. Multiple azides on one substrate were also investigated for their 
reaction rates and were found that when the azides are held in proximity, the rate 
enhancement was disclosed unlike when multiple alkynes were held in proximity. It is 
9 
 
worth to mention that iodoalkynes were found to be more reactive than terminal alkynes  
[13, 14] 
It is worth to state that the advances of click chemistry allowed chemists to design a variety 
of compounds libraries that are wide in scope, and then access the designed library by 
applying the synthetic approach established by K.B. Sharpless.  
1.4. Utilization of Click Chemistry and Natural Pharmacophore in Drug Design and 
Modeling  
Estrogens as a natural product compounds are biologically synthesized by the human 
body through multiple processes starting from cholesterol as starting material [15]. Among 
of estrogen class of compounds are estrone and estradiol, which are identified  
pharmacophores for the estrogen receptors ER [16]. Furthermore, many investigations in 
the estrone-based designed drug candidates have shown potency towards cancer cells such 
as ovarian, prostate and breast cancer [17-19]. Among these investigations, a study 
conducted by Ahmad et al., 2014 established a pharmacophore of cucurbitacin D, a 
naturally occurring compound, on estrone as carrier skeleton for the side chain that is 
responsible for the biological activity [17]. Around these facts, a hypothesis was developed 
assuming that utilizing click chemistry to generate a triazole pharmacophore carried by a 
steroidal skeleton may lead to discovery of novel drug candidates. This assumption was 
packed by findings obtained by Solum et al., 2014, in tubulin polymerization inhibition 
utilizing and cytotoxic effect of estradiol-triazole moieties [19].  
In the literature, many researchers used the same approach to discover new drug 
candidates; for example, a number of steroidal moieties bearing triazole pharmacophore 
were tested for the inhibition of human CYP17 targeting prostate cancer [20]. Another 
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example of utilizing the same approach is observed in incorporation of triazole 
pharmacophore on progesterone, another steroidal hormone, on position 11 by Dhyania et 
al., with uptakes ranging from 5±0.6-35±2.3 % in MCF-7 and HT-29 cells (breast cancer 
cells)[21, 22]. Investigations on the triazole pharmacophore were done by many scientists; 
for example, Kharb et al., have reported the pharmacological profile of triazole derivatives 
with an updated research findings in the discovery of antifungal lead compounds within 
last ten years [22, 23]. On the other hand, Sheng and Zhang reported the structure–activity 
relationship (SAR) of antifungal lead compounds and possibility for future antifungal drug 
discovery [22, 24]. It is explicitly observed that 1,2,3-triazoles are more seen in comparison 
to 1,2,4-triazoles in medicinal chemistry field, including drug discovery utilizing 
computational methods, DNA labeling, bioconjugation, and selective modification of 
enzymes.  
The reason relies behind these various applications is due to the fact that this sequence 
of nitrogen atoms is readily binds with molecular targets through hydrogen bonds and or 
dipole interactions, which lead to solubility. Another interesting feature of 1,2,3-triazoles 
is that they are staple to metabolic degradation which can ensure that the binding with 
molecular targets is affordable [22]. To sum it up, incorporation of triazole pharmacophore 
on the modified estradiol skeleton could lead to a drug candidate discovery.  
The potential of pharmacophore screening in drug discovery encouraged scientists to 
utilize in-silico studies to design novel analogs. To illustrate this point, a summary of 
molecular modeling will be illustrated here.  
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1.5. Molecular Docking 
Molecular docking is very broad topic in the process of drug discovery. Since the 
pharmaceutical industry is growing exponentially, the need of an accurate tool and a 
feasible approach is critical. Molecular modeling is used to predict the behavior and 
performance of every single atom and molecular target in order to anticipate the results of 
the synthetic strategies and conclude the mechanistic pathways by anticipation of transition 
state models. In addition, molecular modeling methods can be used to anticipate the 
behavioral characteristic of molecules toward receptors, enzymes and proteins under 
investigation to further enhance the efficacy of ligand-macromolecule binding which is 
reflected on the potentials of drug candidates [25-27]. Molecular docking is greatly 
appreciated as it is a powerful tool that can predict the physio-chemical parameters of 
ligand, such as absorption, distribution, metabolism, and toxicity utilizing many softwares 
and applications. 
Computational approaches became of great help in drug discovery since 1980s. 
Popular computational methods including structure based drug design, ligand based drug 
design, structure activity relationship (SAR), quantitative structure activity relationship 
(QSAR) and protein binding sites determination are very crucial component in 
computational methodologies, in  all of which, small molecule need to be docked to protein 
binding sites. this is simply referred to as molecular docking [27]. Docking can be utilized 
at different levels of drug discovery and when the crystallography of molecular target is 
well described, high-throughput docking can be used to identify hits for the molecular 
target. In that sense, the aim of docking is to predict and anticipate the binding affinity of 
a ligand with the active site of the molecular target. These binding affinities are based on 
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the arrangement, positions, and conformational structures of ligand on the binding pocket 
of the molecular target. Since docking can lead to a discovery of pharmacophore or a 
template for molecular targets, receptors for example, it is considered logical and 
affordable tool [26]. 
1.5.1.  Scoring Overview 
There are three basic data representations of the receptor, surface, atomic and grid. 
They are representing the significance of protein-ligand interaction. Because of the 
computational complexity of atomic interaction calculations, the ranking procedures of 
atomic representation is utilized with promising energy function. In case of protein-protein 
docking, surface-based docking is used. In many docking programs, potential energy grids 
are used to calculate the energy. Grid-based methodologies utilize grid points to collect 
electrostatic potentials in addition to Van der Walls potentials [28]. The term search 
algorithms refer to the algorithm used to calculate the ligand flexibility and inferior 
quantity of receptor flexibility. Dealing with ligand flexibility is classified into 1) 
simulation methods 2) random, and 3) systematic. Simulation-based search methods are 
usually depending on the simulation of molecular dynamics. Since the main limitation of 
initiation of flexibility is the rely on higher energy barriers; the simulations will not pass 
the high-energy barriers in efficient time period. Therefore, protein flexibility is less 
efficient than ligand flexibility [27].  
Alternatively, random-based search methods are simply make multiple alterations 
on the ligand to sample some degree of freedom. An example of random based-search 
methods is Monte Carlo & genetic algorithms. Lastly, systematic-based search methods 
are attempting to seek degree of freedom in molecule. Systematic search also can use rigid 
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structure that been pre-generated with diverse conformational poses (as openeye® 
employs). The computational expense in this method is reduced due to the performance of 
this method, in which the conformations are calculated first at once [28].  
It is worth to point out that the advances of molecular modeling paved the way to 
use this technique in drug discovery. 
1.5.2. Types of Scoring Functions 
The aim of scoring functions is to effectively calculate and measure the ∆G of the 
complex binding results from the interaction between the ligand and the receptor. These 
calculations and measurements are considered expensive, therefore, many speculations are 
made in sake of the completion of these calculation and measurement in a reasonable time 
manner [27]. Scoring function can be classified in three types, force field based, empirical 
based and lastly knowledge based [27, 29]. In the force field scoring, the molecular 
mechanics consider the sum of two energies. That means, the sum of the energy of receptor-
ligand interactions, and the energy of internal ligand. In general, many of force field scoring 
functions are designed for single protein. for that reason, it is reasonable to remove the 
thermal protein energy calculations [26, 27, 29]. Force filed scoring functions are based on 
many parameters such as, MMFF94, AMBER, OPLS-AA and tripos force field. Van der 
Waals and electrical static energy can be used as well to describe the ligand-receptor 
interactions. Furthermore, Lennard-Jones potential function is used to describe Van der 
Waals energy. While coulombic formulations are used to describe the electrostatic terms. 
These coulombic formulations are usually with distance-dependent dielectric function, 
which limits the contribution resulting from charge-charge interactions [26, 27, 29].  
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Empirical scoring functions are based on the sum of many terms. Mainly, experimental 
data regarding the calculated value of binding affinities and the calculated value of binding 
energies, As well as the x-ray crystal structures are utilized to calculate the coefficients of 
these terms. Not only binding energy can be utilized in scoring functions, but also 
experimental 3-D structural databases can also be utilized too. In this sense using the simple 
potentials of atomic interactions, protein-ligand complex can be modeled [27]. 
  Computational simplicity and efficacy are the most important feature of these 
scoring functions. These features particularly made screening of large numbers of analogs 
more efficient. However, because of the conclusion of scoring functions is based on the 
information obtained from the limited sets of protein-ligand structures, it is not accurate to 
assume that a single scoring function can fit for all types of interactions of the protein-
ligand complexes. Therefore, combining the collected data from these different scores, 
which is knowing as consensus scoring is frequently used as consensus scoring balance the 
errors resulting from each single score. The advantage of consensus scoring is clearly 
observed in its ability to increase the percentage and ranking of the hit in comparison to 
the entire library in docking process [27, 29-32]. 
To sum up, modeling is a powerful tool that can be used to determine the potential analogs, 
which can be optimized to enhance the biological screening in order to evaluate the 
synthesized analogs. 
1.5.3. Docking Drawbacks 
Docking limitations basically come from the accuracy of the prediction of enthalpic 
and entropic effects. In addition, the conformational alterations during binding as well as 
the crystallography structure are playing major effects. Because of that, docking and 
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scoring are usually build up from many processing steps. Initially it begins with placing a 
molecule, ligand, into the binding pocket of the receptor. This placing must take in 
consideration the optimal interactions with the receptor, subsequently, the optimal 
interaction will be evaluated based on certain calculation, this process is known as scoring 
function, which is eventually tell the difference in terms of affinity of the library of ligands 
[31]. 
1.6. Role of The Epidermal Growth Factor Receptor in The Treatment Of CRC 
Epidermal growth factor receptor (EGFR) is a member of tyrosine kinase receptors 
family, which consists of EGFR (erbB1/Her1), Her2/neu (erbB2), Her3 (erbB3), and Her4 
(erbB4). EGFRs have a natural ligand, which is the epidermal growth factor (EGF) [33]. 
EGFR consists of three domains, an extracellular ligand-binding domain, a 
cytoplasmic tyrosine kinase domain and lastly a single membrane-spanning region (Alroy 
and Yarden, 1997; Normanno et al., 2006) [34, 35]. The ligand, as a stimulating factor, 
binds specifically to the extracellular domain leading to receptor homo- or hetero-
dimerization, which promotes conformational change of the intracellular phosphorylation 
components, which enables the downstream signaling [36]. The downstream signaling 
cascades has many pathways including RAS-RAF-MAP kinase pathway Figure 1.1  [35], 
the phosphatidyl inositol 3-kinase (PI3K) and the Akt pathway (Burgering and Coffer, 
1995)  [37, 38]. These signaling pathways contribute in cell survival, activation, cycle, 
proliferation, and angiogenesis [39, 40]. 
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Figure 1.1. The EGFR signaling pathway overexpressed in CRC. 
The significance of EGFRs stimulation pathways is relying behind the fact that it 
promotes tumor cell motility, metastasis and adhesion [41]. In that sense, there is no doubt 
that this led scientist to investigate more in EGFR inhibitors and come up with many EGFR 
inhibitors including cetuximab, panitumumab (both are FDA approved treatment for 
metastatic colorectal cancer (mCRC)), as well as erlotinib  and gefitinib,  which are 
another example of  anti-EGFR tyrosine kinase inhibitors (TKIs) for the treatment of other 
malignancies [42]. 
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1.7. Colorectal Cancer Diagnosis 
Around the world, colorectal cancer detection is the main challenge that faces 
physicians. Therefore, many physicians recommend certain screening tests for people with 
no signs or symptoms of colorectal cancer, to ensure the health status of individuals. 
According to Sidney et al., these screening tests are of great advantage in diagnosis of 
colorectal cancer at early stages, which helps to treat the disease and to reduce the risk of 
dying [43]. Screening tests should be considered for the people at age 50 since it is the age 
of highest risk. While people of hereditary history of the disease should consider screening 
test sooner. In addition, African-American as well as native American should consider 
these tests at age 45 [43-45]. These screening test are primarily centered on colonoscopy, 
which is a flexible long slender tube  attached to a camera that is inserted to the body to 
look at the colon and rectal areas as well [44]. It is important to notice that CRC diagnosis 
enable to classify CRC stage and consequently lead to determine therapy regimens. 
1.7.1. Colorectal Cancer Stages and Treatment 
Patients diagnosed with colorectal cancer will be asked to preform serval tests to 
show the extent of the cancer stage in a procedure known as stage diagnosis. Physicians 
use this staging diagnosis to decide which treatment is suitable with the disease. The 
process of staging diagnosis includes imaging techniques such as abdominal and chest CT 
scans [46]. According to tumor, node, metastasis system (TNM) colorectal cancer is 
classified into four stages. In stage I, cancer has grown through the mucosa of colon or 
rectum but did not spread out of this region. In this stage, the better treatment would be 
surgery, in which cancer tumor can be removed from the body. Stage II colorectal cancer 
means that the cancer cell has not spread to other lymph although it has spread and grew 
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through the colon or rectum walls. According to American Cancer Society (ACS) the 
treatment of the cancer at this stage would be also by a surgery and the physician would 
advise the patience to do more surgeries until the cancer tumor is removed from the polyp 
in addition to chemotherapy after surgery [47]. Stage III means that the cancer has spread 
through the rectum or colon walls and invade nearby lymph nodes but did not spread into 
different organs or other body compartments. At this stage, chemotherapy could be the 
better treatment in addition to surgery as well. As for chemotherapy, many physicians 
recommend FOLFOX, which is composed of leucovorin (Folinic Acid, chemo-protectant 
drug side effect and 5-FU) and oxaliplatin. alternatively, the physician could also 
recommend CapeOx, which is a regimen that consists of capecitabine and oxaliplatin [48]. 
Chemotherapy and surgery are not the only treatment of CRC stage III, radiation could also 
be utilized to kill cancer cells in case of the surgeons thought that some of the caner tumor 
cannot be removed surgically [49, 50]. Lastly, stage IV CRC means that the cancer has 
spread to distant organs and affected the tissues of the new organs, which also known as 
metastasis [51]. It is worth to notice that CRC stage IV is commonly diagnosed as well 
with liver cancer [52]. Figure 1.2 shows the chemical structure of CRC approved 
chemotherapy [48, 49, 53]. 
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Figure 1.2. Commercially available and FDA-approved chemotherapy of CRC. 
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1.7.1.1. 5-Fluorouracil Chemotherapy 
5-fluorouracil (5-FU) is a fluoropyrimidine based compound that is widely used as 
chemotherapy for colorectal cancer as and breast cancer [49]. The anticancer activity of 
this drug comes from the inhibition of thymidylate synthase (TS) and incorporation of its 
metabolites into DNA and RNA [49, 54, 55]. Co-treatment with leucovorin and 
methotrexate as a modulation strategy of this drug have been utilized and showed a good 
profile of anticancer activity for 5-FU. The metabolic pathways of 5-FU have been studied 
and it was found that Dihydropyrimidine dehydrogenase (DPD) converted 5-FU to three 
active metabolites, fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine 
triphosphate (FdUTP), and lastly fluorouridine triphosphate (FUTP). The activation of 5-
FU is generated by the conversion of 5-FU into fluorouridine monophosphate (FUMP), 
which can be achieved by conjugation of phosphoribosyltransferase (OPRT) with cofactors 
such as phosphoribosyl pyrophosphate (PRPP), or indirectly by the subsequent action of 
uridine kinase (UK) and uridine phosphorylase (UP) [49].  
Consequently, FUMP is further phosphorylated into fluorouridine diphosphate 
(FUDP). Similarly, FUDP can be further phosphorylated into fluorouridine triphosphate 
(FUTP), the active metabolite, or converted to another form of metabolite, 
fluorodeoxyuridine diphosphate (FdUDP), utilizing ribonucleotide reductase (RR). 
FdUDP fate in the body could be carried on for further phosphorylation to generate FdUTP. 
Alternatively, FdUDP could also dephosphorylated to generate FdUMP. Another pathway 
could occur involves the generation of fluorodeoxyuridine (FUDR) by the conversion of 
5-FU utilizing the thymidine phosphorylase catalyzed conversion followed by 
phosphorylation by thymidine kinase (TK) to generate FdUMP. It is worth to notice that 
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the main side effect of 5-FU is reducing the white blood cells significantly, which may lead 
to infection, which put a significant need for new chemotherapy [49, 54, 56].   
1.7.1.2. Oxaliplatin 
Oxaliplatin is one of the FDA approved drugs for CRC since 1996. Normally, 
oxaliplatin is used together with folinic acid and fluorouracil. Oxaliplatin has a 1,2-
diaminocyclohexane (DACH) ring as a carrier ligand which gives the drug an efficacy in 
comparison to other carrier ligands especially in the cisplatin resistance [53]. In addition 
to that, DACH can guide the interaction of Pt with the DNA.  There are three possible 
conformations for DACH carrier ligands trans L(R,R), trans-d(S,S) and cis(R,S). studies 
show that trans L(R,R) is the most affective conformation of DACH in cytotoxicity assays 
in comparison to the other two conformers. The logic explanation of this efficacy is 
possible considering the differential recognition of the isomer by damage processing 
complexes and/or damage recognition proteins [53, 57]. The mechanism of action of 
oxaliplatin is similar to cisplatin, a very well-known drug for ovarian cancer. The 
mechanism of action is mediated by formation of Pt-DNA adduct. Consequently, when the 
oxaliplatin penetrate the cell, it loses a chloride ligand to form a highly reactive 
monoaquamonochloro species, which rapidly reacts with the nitrogen on position 7(N7) of 
the guanine attached to DNA [53]. Similarly, the second chloride ligand dissociates to form 
multiple stable adducts mainly intrastrand adducts with DNA. It is important to highlight 
that oxaliplatin is not specific to the molecular target encoded as KRAS in the downstream 
signaling pathway of the EGFR [48, 53, 57-59].  
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1.8. Examples of Biologically Active 1,2,3-Triazoles  
Although the number of molecules bearing 1,2,3-triazoles in the market are limited, 
needless to say in the advanced clinical trials; however, there are number of potential drugs 
including antibacterial, anticancer, HIV protease inhibitors, and anti-tuberculosis. 
Examples of these classes will be discussed in this section with details [22]. 
1.8.1. Anti-Cancers 
Cancer is the major health concern in developing and developed countries. 
Therefore, it captures the interest of chemotherapeutic industry. There are several anti-
cancer drugs in the market such as taxol, topotecan, irinotecan and vincristine. In addition, 
many anti-cancer drugs in the premarket stages such as flavopiridol, betulinic acid, 
roscovitine, and silvestrol. However, the realm of anti-cancer drugs may witness new 
candidates. Fray et al., reported hit compounds based on 6,7-dichloro-1,4-dihydro-
(1H,4H)-quinoxaline-2,3-diones nucleus, where position 5 is substituted with 
heterocyclylmethyl or 1(heterocyclyl)-1-propyl group [22]. Several novel hits contained 
1,2,3-triazole ring, most recently potent compound a 6,7-dichloro-5-[1-(1,2,4triazol-4-
yl)propyl]-1,4-dihydro-(1H,4H)-quinoxaline-2,3dione, which has remarkable brain 
penetration. Another example of anti-cancer candidates bearing 1,2,3-triazole is 4-aryl-
1,2,3-triazoles, which is an inhibitor of human methionine aminopeptidase type 2 
(hMetAP2) (Kallander et al.,). The inhibition mechanism of this candidates relies behind 
the ability of N1 and N2 to bind with the enzyme active site which results in the inhibition 
behavior of this drug [60]. 
  Derivatives of available drugs were designed to bear 1,2,3-triazole moiety were 
also became of interst to chemotherapeutic industry, for example, resveratrol triazole 
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derivatives were synthesized by Pagliai et al., and many of these compounds showed 
antiproliferation activity [22, 61]. Another example shows the anti-cancer capability of 
1,2,3-triazole is the work done by Lee et al., A series of 1,2,3-triazole-containing a-GalCer 
analogues as agonistic antigen killer of T-cell receptor were prepared. The creativity of his 
work was achieved by the replacement of the amide of α-GalCer by a triazole ring which 
increased the reactivity significantly [22, 62].   
The work done by Pisaneschi et al., shows the tendency of 1,2,3-triazoles to bind 
with Epidermal Growth Factor Receptor (EGFR), which is a receptor that normally 
overexpressed in many cancers including ovarian, breast, and lung cancer [22, 63]. 
Pisaneschi et al., synthesized a small library of fluorine-containing compounds based on a 
3-cyanoquinoline nucleus in order to discover an EGFR-specific imaging agent. [64] these 
derivatives were selected based on their high affinity for EGFR kinas (IC50=(1.81±0.18) 
nm), fair cellular potency (IC50=(21.97±9.06) nm), limited lipophilicity, and accepted 
metabolic stability. Among this library, the compound possesses 20-fluoroethyl-1,2,3-
triazole was examined for radioligand activity and the result showed acceptable stability in 
vitro and the uptake was fourfold-higher in high EGFR-expressing A431 tumor xenografts 
relative to low EGFR-expressing HCT116 tumor xenografts [22, 63]. 
1.8.2. HIV Protease Inhibitors 
Since 1981 AIDS results in death of 20 million people around the world. The 
control of this drug may rely behind the inhibition of the viral replication. HIV-1 protease 
(HIV-1Pr) became the molecular target to inhibit and hence control the disease and due to 
the increasing rate of the viral resistance, the need of wide spectrum of protease inhibitors 
has emerged [22]. One attempt to achieve this goal was done by Whiting et al., who has 
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built up a focused library of 1.4-disubstituted 1,2,3-triazole from multi functionalized 
alkynes [64]. Interestingly, the assembled triazoles exhibit a high binding affinity to human 
immunodeficiency virus type-1 protease. Furthermore, increasing the substitution degree 
on the triazole ring by functionalizing position 5 has led to increased binding affinity as 
well as low Ki values (Ki =8 nM). Finally, ribavirin is an anti HCV inhibitor which have 
been derivatized by Saito et al., with carbocyclic and phosphonocarbocyclic analogues and 
were evaluated against HCV and other viruses and exhibit fair IC50 against HIV-1 [22, 64]. 
1.8.3. Antituberculosis inhibitors 
Tuberculosis (TB) is a major leading cause of mortality. World Health Organization 
(WHO) has approved a treatment for TB known as directly observed therapy short-course 
(DOTS), which comprises three or four drugs including, isoniazid, rifampin, pyrazinamide, 
and/or ethambutol for a minimum of six months of treatment. However, these first-
generation remain useful in treating susceptible Mycobacterium Tuberculosis strains, 
therefore, a new multidrug-resistant tuberculosis are crucially wanted [22, 65]. 
Rationally designed nucleoside reported by Somu et al., and found to be a good inhibitor 
of Mycobacterium Tuberculosis that disrupts the siderophore biosynthesis [66]. The 
activity of this nucleoside was proven to be due to inhibition of the adenylateforming 
enzyme MbtA, which is an enzyme involved in the biosynthesis of the mycobactins [22, 
66]. 
Costa et al., reported a two series of compounds that bear 1,2,3-triazole with 
antimycobacterial profile [65]. The in vitro screening of anti-tuberculosis of these series 
explains that the triazole-4-carbaldehyde derivatives were more effective than the 4-
difluoromethyl derivatives; moreover, the importance of hydrogen-bond acceptor, and its 
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position in the aromatic ring, in addition to the planarity of triazole and phenyl rings were 
investigated by structure activity relationships studies (SAR) and showed an importance 
for the anti-tubercular activity [22, 65]. 
1.8.4. Antifungals and Antibacterials 
Continuous use of immunosuppressive drugs in addition to continuous use of wide 
spectrum antibiotics, have led to the spread of life-threatening fungal infections in the last 
two decades. Furthermore, the antifungal approved treatment present today in the market 
are either toxic or ineffective in the long use due to the resistant strains, which triggered 
the research of finding new drugs in new chemical classes. among these classes. Many 
classes including 1,2,3-triazoles were subjected to investigation. 
A series of fluconazole/bile acid conjugates at C3 and C24 positions of bile acids 
were designed and synthesized by V.S Pore et al.,[67]. These new triazole- bearing 
molecules showed an excellent antifungal activity against Candida species. The MIC 
values of these compounds varies between 3.12 to 6.25 mg. mL-1. Studies suggest that the 
biological activity of this class was due to the bile acid moiety, which plays a drug carrier 
role, while the fluconazole moiety plays an inhibitory role. It is also noted that the 
functionalization of position 4 was clearly increasing the activity [22, 67]. 
The synthesis and biological evaluation of novel oxazolidinones bearing a 4-
substituted 1,2,3-triazole moieties were reported by Reck et al., [68]. The access to this 
class of compounds was achieved by Vinylsulfone and tosylhydrazone reagents. The 
biological activity studies reveal that functionalized C 4 of the triazole ring with a small 
substituent bearing an sp or sp3 center, were potent antibacterials against Gram-positive 
25 
 
bacteria. in addition, a number of these compounds were also found to be an excellent 
inhibitors of monoamine oxidase A (MAO-A) [22, 68, 69]. 
 There is a tremendous amount of related data in the literature illustrates that 1,2,3-
triazole ring is a potential pharmacophore for many diseases, and based on that a hypothesis 
was developed, by assembling a triazole pharmacophore on a carrier such as estradiol could 
enable targeting overexpressed macromolecules in colorectal cancer. To test this 
hypothesis, three objectives were formulated, 1) to design and virtually screen a library of 
triazole-based estradiol ligands on macromolecules expressed in CRC. 2) to synthesized 
the promising candidates of the designed ligands based on their consensus scoring in the 
docking study, and 3) to biologically test the synthesized ligand on different CRC cell lines. 
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 CHAPTER TWO 
DESIGN OF 1.4-DISUBSTITUTED 1.2.3TRIAZOLES TARGETING EPIDERMAL 
GROWTH FACTOR RECEPTORS (EGFRS) 
 
2.1. Introduction 
1,2,3-triazoles are non-naturally occurring compounds that are synthesized in 
laboratories utilizing a well descried reaction called click chemistry [8]. Furthermore, data 
gathered from multiple perspective concluded that 1,2,3-triazoles could be a possible 
inhibitors for many receptors signaling pathways as well as a pharmacophore for many 
diseases [22]. Among these diseases is cancer, the very same disease that considered a 
threat to many lives in the united states let alone the entire world.  Since the inhibitory 
behavior of 1,2,3-triazoles for the epidermal growth factor receptors (EGFRs) is known, 
the aim of this part of the research is to investigate the binding affinity of estradiol-1,2,3-
triazole analogs towards a selected EGFR signaling cascade, utilizing the modeling studies 
as well as the biological study [70, 71].  
To achieve this goal, molecular modeling approaches including in-silico studies 
conducted on the downstream signaling cascade of EGFRs including MEK, ERK, RAF, 
and RAS. Estrogens are a naturally occurring hormone that is secreted by the ovary in the 
human body. they regulate and differentiate the growth of reproductive system; 
consequently, it influences the pathological development of hormone dependent cancer. In 
addition to that, it is known that estrogens can penetrate the cell and based on that were 
chosen to carry the 1,2,3-triazole fragment as potential inhibitors for EGFRs [72-74]. 
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Epidermal growth factor receptors are overexpressed in many types of cancers including 
colorectal cancer. To illustrate more, types of cancer that utilized EGFRs can be classified 
into 4 groups.1) endocrine gland cancers including adrenocortical carcinoma, ovarian 
cancer, pancreatic cancer and prostate and thyroid cancers. 2) breast and gynecologic 
cancers including cervical endometrial cancer and ovarian cancer. 3) lung carcinoma and 
finally. 4) digestive cancers which include colorectal cancer, esophageal cancer, liver 
cancer and pancreatic cancer Based on these facts, estradiol-1,2,3-triazole analogs and 
epidermal growth factor receptors were the focus of the modeling in this research [74, 75].  
Structural modification on various positions of estrone skeleton have been studied 
before, and showed an enhanced biological activity. Estrone modification can be classified 
into two distinct categories 1) adding different moieties to the estron skeleton in different 
positions and 2) adding a heteroatom to the steroidal ring system or by ring expansion of 
one of the estradiol tetra cyclic system as shown in Figure2.1. Due to the complexity of 
the latter, it is reasonable to conclude that based on the current literature the first category 
of modifications is the most popular method used to enhance the biological activity [76, 
77]. 
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Figure 2.1. distinct positions of estrone and steroidal skeleton that been extensively 
modified and proven to enhance biological activity. 
Modification on position 2 of the estrone skeleton by introducing sulfamte group 
has significantly reduced the estrogen undesired side effects as well as increasing the anti-
proliferative activity in breast cancer cell [78]. Triazolyl functionalization on position 3 
utilizing propargyl azide-cycloaddition has resulted in enhanced anti-cancer proliferation 
with IC50=0.3-0.9µM Bodnar et al., [79]. Not only position 2 and 3 were investigated but 
also position 17 was subjected to several investigations too. For example, Ahmad et al., 
2014 proved that acquiring a cucurbitacin side chain on position 17 have led to a potency 
in the inhibitory activity to the MAPK signaling pathway toward the treatment of 
melanoma [17].  
2.2. Molecular Modeling and Rational Design of 1,2,3-Triazol Bearing Inhibitors.  
2.2.1. Protein Kinases 
2.2.1.1. Methods of Molecular Modeling  
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All the computer-based experiments were conducted on a Gateway Computer with 
Windows XP operating system. 
2.2.1.2.  Molecular Modeling of 2-D and 3-D Structures 
A virtual library of 800 compounds bearing estradiol-1,2.3-triazole analogs were 
assembled on position 17 of the steroidal skeleton. Additionally, a selection of known 
inhibitors to the EGFR as well as known chemotherapeutics for CRC were used as 
standards in the docking process. The virtual library including the standards were 
assembled and energy minimized using Chemoffice 2012, utilizing MMFF94 calculation 
for energy minimization purposes. The energy minimization calculations were aim to 
obtain a similar structural confirmation mimic to the natural 3-D structure for each 
compound designed. 
2.3. Utilization of OMEGA to Generate Structural Conformers 
All the compounds that been energy-minimized were converted into pdb formats. 
consequently, all the generated pdb files were gathered in one pdb file containing all the 
minimized compounds including standards. The purpose of this step is to use this pdb file 
as an input parameter for OMEGA calculations. OMEGA calculations include creation of 
multiple and different conformers of each designed compound in the virtual library 
utilizing the MMFF94 calculations in order to perform ligand-protein flexible docking. 
Multiple modifications on the default setting of OMEGA were conducted. These 
modifications include reject conformers that possess an energy different to the global 
minimum of >5.0 kcal/mol (GP_ENERGY_WINDOW). Additionally, maximizing the 
number of output of conformers to 400 (GP_NUM_OUTPUT_CONFS) and finally, 
selection of the low energy of conformers from the final ensembled compounds 
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(GP_SELECT_RANDOM false) taking in considerations the root-mean square deviation 
(RMSD) cut-off of 0.8 A° (GP_RMS_CUTOFF). additionally, increasing the rotatable 
bonds in the designed molecules to 30 for each conformer (GP_MAX_ROTORS) the 
purpose of these modifications is to generate conformers for all of the designed ligands in 
the data obtained from the virtual library [73].  
2.3.1. Utilization of FRED to Prepare the Receptors 
Protein data bank was the only source of all the receptors under investigation. All 
the receptors were downloaded as PDB files. The receptors under investigation were 
known for their high expression as well as they consistent in their pathway toward the 
signaling that lead to the cell proliferation. The following receptors were chosen (PDB ID 
in parentheses) to conduct the docking study, epidermal growth factor with tyrosine kinase 
domain (PDB ID:1M17), RAS (4DST), RAF (PDB ID: 3OMV, 3PRF), MEK1 (PDB ID: 
3PP1), ERK2 (PDB IDs:1TVO & 2OJJ), and CDK (PDB ID: 3QL8) Figure 2.2. FRED-
make receptor, a software that OpenEye® offers, was utilized to prepare all the receptors. 
A part of FRED-make receptors software is the graphical visualization which was utilized 
to prepare the receptors. FRED-make receptor consists of three components, mode 
selection, control and 3D visualization window. FRED-make receptor process in receptors 
preparation can be summarized in three steps, FRED-make receptor is used to open the 
PDB file of the receptor then convert it into a 3D view of the whole receptor including the 
receptor’s binding pocket, ligand and cofactors. Consequently, utilizing the binding pocket 
of the receptor, which usually coexisted with a bounded ligand, in the mode selection 
window to generate the grid box in a specific size (less than 60.000 Aº).  
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It is worth to mention that in case of larger grid sizes were needed, the grid box 
must be split into two parts. This step is crucial as the docking process will not proceed 
properly otherwise. Finally, mode selection window will generate a final shape of the 
binging pocket, as FRED will guide the docking process to the specific site and shape of 
the prepared receptor with their inner  
and outer shells. Conducting these three steps in a chronological manner will ensure 
that the receptor is ready to execute the docking on [80].  
Figure 2.2. Epidermal Growth Factor Receptor Tyrosine Kinase domain with4-
anilinoquinazoline inhibitor erlotinib. (PDB ID: 1M17) 
2.3.2. Conducting Docking Using FRED 
FRED generates a fit-shapes in a shape fitting step, in which FRED locates the three 
dimensional area where the algorithmic search is preformed, this particular step allows 
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FRED to recognize the possible shapes for the calculations and hence the docking [80]. 
The shape fitting step ensure that the three dimensional-shaped area is located properly for 
the ligand and the best binding pocket will ensure to avoid the unnecessary binding with 
other sites of the receptor, in addition to simultaneously flipping the area of binding to 
ensure the optimum interactions occur in the pocket. Lastly, the PDB file of the combined 
library, including standards, as well as the prepared receptors were collected by FRED to 
perform the docking process. There are multiple optimization steps for the scoring 
functions, including rigid skeleton optimization, torsion optimization and -OH groups 
rotamer optimization [81].  
Consensus score can be obtained utilizing multiple scoring functions when the docking 
process reaches the final steps. These scoring functions that shape the consensus score, in 
a chronological manner, includes, shapegauss, chemgauss3, oechemscore, screenscore and 
finally PLP. More information regarding each scoring function can be obtained from 
OpenEye® FRED website www.eyesopen.com/products. Additionally, the three-
dimensional conformers for each ligand and receptor can be visualized by OpenEye® VIDA 
and from which all the figures (in the result and discussion section) were taken from [81]. 
2.4. Results and Discussion 
  The virtual library of estradiol-1,2,3-triazole analogs as well as three standards 
including FDA-approved and commercialized drugs were docked on six different receptors 
starting from the overexpressed receptor extracellular domain (1M17), and ending to the 
downstream singnaling cascade including Raf, Ras, ERK and MEK. The novel estradiol-
1,2,3-trizole analogs were designed in systematic manner by1) functionalization of position 
17 of the estradiol by the trizolyl moieties including 1,4-disubstituted trizole and 1,4,5-
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trisubstituted trizole, where C 5’ of the triazole ring is functionalized with phenyl and 
carbinol groups. 2) Functionalization of position 3 of the estradiol with the following 
groups: -OH, -Me, -AcO, -SO2NH2, -(CH3)3CCO, -Bn and -CH2C6H5X, where X= 
F,Cl,Br,I, CH3 and OCH3 on para, ortho, and meta positions. Lastly functionalization of 
position 16 and 17 by introducing double bond, which results in a significant change of the 
conformation of the triazole ring in addition to removing an OH group which is possible 
hydrogen acceptor. An average of 114 analogs showed better binding affinity to the 
receptors (appendix 1). These binding affinities expressed as a lower consensus scores 
than the known inhibitors such as erlotinib 5-Fu, capecitabine oxaliplatin, Figure 2.3 
illustrates numerous examples of the library. 
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Figure 2.3. The variety of functionalization of the estrone-trizole analogs.  The 
functionalization took place on C3, C16, C17, C18 and N1. 
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To sum it up, the virtual library can be divided into three groups based on the 
substitution of the triazole ring.  
Group 1, where is no substitution on position 5’ of the triazole ring, and it is the 
majority of the hits in EGFR. Group 2, where the substitution on position 5’ of the triazole 
ring is carbinol group and Finally, Group 3, where the substitution of position 5 is a phenyl 
ring, and interestingly enough, even though the phenyl ring can offer a hydrophobic feature 
and hence, become the mode of action in hydrophobic pockets, however most of the trends 
in hydrophobic pockets is the mild polarity that the trazole ring possess. To put it 
differently, lack of substitution on position 5’ in addition to bearing a hydrophobic group 
on R2 of the triazole is the trending mode of action. Figure 2.4 shows the selected 
compounds for the synthesis.  
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Figure 2.4. Group 1 trending compounds, all the compounds in this group lack 
functionalization in C18 (C5 ′ in the triazole ring) 
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2.4.1. Result and Discussion of Molecular Modeling with EGFR  
The docking study conducted on epidermal growth factor receptor tyrosine kinase 
domain (1M17) showed an interesting binding mode. The trending mode of action was 
the following: functionalization of position 3 of estradiol with hydrophobic groups such 
as benzyl group or methyl group and lack of substitution on position 5’ of the triazole 
ring was dominant. In addition, the group that the triazole ring bears at position 1’ (N1) 
was fairly polar. Examples of the substituents at position 1 are 1-N-acetylindole, N-
acetylaniline, N-acetylmethoxybenzene, N-acetylmorphiline and N-acetylpipridine. The 
previous trend was founded in the following compounds: FZ 600, FZ 100, FZ514, FZ 
516, FZ 518, FZ 560, FZ 313, FZ560, FZ 100. Figure 2.7 shows the presence of indole 
nucleus is important in the binding of the ligands to the pocket. This binding is through 
the N2 and N3 of the triazole ring. 
 
 
 
 
 
 
 
 Figure 2.7. FZ 518 and 5-FU as a standard which binds with 
GLU783 A and ASP831 A and THR 830A via three hydrogen 
bonds. 
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It appears that the indole ring can deliver the ligand closer to the pocket and into 
the space that is required to form the hydrogen bond. This trend is noted in FZ 514, FZ 516 
and FZ 518. On the contrary, the absence of an indole ring changed the trending to a 
hydrophobic interaction when the substituent on N1’ of the triazole ring bore an aromatic 
amine. Figures 2.8. show the aromatic amines effect on the binding mode. It is noted that 
the aromatic amine is occupying a space out of the binding pocket. This mode of action is 
observed in the following compounds: FZ57, FZ60, FZ 200, FZ 300, FZ 313 and FZ 400. 
An exception is FZ 313, where the OH group at position 3 has a hydrogen bond with PRO 
770 A.  
Overall, this mode of action differs due to the presence of a highly hydrophobic 
group attached to the amine, which is causing a hydrophobic interaction that orients the 
hydrophobic group outside the binding pocket. Additionally, hydrogen binding took place 
in only one instance, by increasing the hydrophobicity on the amine side and having mild 
polarity on position 3 (FZ 313). Table 2.1 sums up the functionality responsible for the 
binding.  
Similarly, replacing R3 with slightly polar heterocyclic amino groups, such as 
morpholine and Piperidine nucleuses (Figure 2.9 A&B), have the same implications for 
the binding mode, which is clearly observed in the following ligands: FZ 100, FZ 552, FZ 
556, and FZ 600. Table 2.2 summarizes the mode of action of the last group. 
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Figure 2.8. FZ 200 and 5-FU, the latter binds with GLU783 A and ASP 831 A 
and THR 830 A via three hydrogen bonds. 
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Table 2.1: Summary of the binding mode of actions of hydrophobic aromatic analogs. 
Compound R1 R2 Mode of Action 
Aromatic Ring 
Orientation 
FZ 25 OBn H 
Hydrophobic 
interaction 
No aromatic ring 
present. 
FZ57 OBn PhNHCOCH2- 
Hydrophobic 
interaction 
Out of the pocket 
FZ 60 OH PhNHCOCH2- 
Hydrophobic 
interaction 
Out of the pocket 
FZ 200 OAC PhNHCOCH2- 
Hydrophobic 
interaction 
Out of the pocket 
FZ 300 OH CH3OPhNHCOCH2- 
Hydrogen bonding/ 
PRO 770 A 
Out of the pocket 
FZ313 OH CH3PhNHCOCH2- 
Hydrophobic 
interaction 
Out of the pocket 
FZ 400 OBn CH3PhNHCOCH2- 
Hydrophobic 
interaction 
Out of the pocket 
 
Table2.2: Summary of the mode of actions in compounds that exhibit an orientation of 
the heterocyclic ring outside the binding pocket. 
Compound R1 R2 Mode of Action 
Heterocyclic amine 
Ring Orientation 
FZ 100 OH C4H8ONCOCH2- 
Hydrogen Bonding/ 
PRO 770 A 
Out of the pocket 
FZ 552 OMe C5H10NCOCH2- 
Hydrophobic 
interaction 
Out of the pocket 
FZ 556 OAC C5H10NCOCH2- 
Hydrophobic 
interaction 
Out of the pocket 
FZ 600 OH C5H10NCOCH2- 
Hydrophobic 
interaction 
Out of the pocket 
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B 
A 
Figure 2.9. (A) both rings are outside of the pocket. However, FZ 100 
shows hydrogen binding with PRO 770 A. FZ 100 containing 
morpholine ring (B) FZ 600 containing Piperidine ring in the binding 
pocket. 
A 
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2.4.2. Result and Discussion of Molecular Modeling with RAF receptors 
2.4.2.1 Result and Discussion of Molecular Modeling with 3PRF 
The result of the docking study conducted on the B-Raf Kinase Domain (3prf) 
showed similar results in comparison to 1M17. The presence of an indole nucleus showed 
hydrophobic interaction; however, there were no hydrogen bonds involved in the binding 
(Figure 2.10). On the contrary, both ligands, 5-FU and capecitabine, bind with two amino 
acids present in the binding pocket. 
 
 
 
Similarly, an aromatic amine containing triazoles exhibits hydrophobic 
interactions, except with the mild polarity on position 3, which results in hydrogen binding 
Figure 2.10. FZ 516 containing indole ring (light-blue), 5FU 
(gold) which fits the binding pocket with hydrogen bonding with 
CYS 531B and CYS 532B  
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with CYS532 B. This mode of action is noticed in FZ57, FZ60, FZ 200, FZ 300, FZ 313 
and FZ 400. Figure 2.12 shows the binding affinity modes in this set of ligands. 
 
 
 
Alternatively, the last set of compounds (3compounds) have a different mode of 
action. The piperidine nucleus-containing compound binds with SER 535 B (the same 
amino acids bind with capecitabine) through the OH existing on position 17 (FZ 552, FZ 
600 and FZ 556). On the other hand, the morpholine-containing triazole binds with a 
different amino acid (SER 536 B) utilizing N2 on the triazole ring. Figure 2.13 A-F shows 
the visual representation of these binding affinities. Table 2.3 summarizes the binding 
mode of action from many perspectives. 
Figure 2.12. FZ 60 (Yellow) and 5-FU (Gold) which bears two 
hydrogen bonds, and CYS 532 B and TRP 531 B as the design ligand. 
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Table 2.3: Summary of the binding modes of action of the last set of compounds in three 
perspectives. 
Type of amine 
attached to 
triazole 
Type of interaction 
Orientation of 
Amine 
Indole bearing 
triazole. 
Hydrophobic. 
Inside the 
pocket. 
aromatic bearing 
triazole. 
Hydrophobic, except OH on C3. 
Inside the 
pocket. 
Aliphatic bearing 
triazole. 
Hydrogen bonding utilizing OH on C17, 
except with morpholine bearing triazole 
binds with N2. 
Inside the 
pocket. 
 
2.4.2.2. Result and Discussion of Molecular Modeling with 3OMV. 
The binding affinities of RAF-1 (3OMV) are different than the binding affinities in 
B-RAF Kinase Domain (3prf). The presence of an indole ring attached to the triazole 
fragment establishes a hydrogen bond with the hydroxyl group present in position 17 with 
GLY 426 (Figure 2.14 A). On the other hand, 5-Fu binds in the same pocket with CYS 
424 A with one hydrogen bond (Figure 2.14 B). Lastly, capecitabine binds with LYS 431 
A utilizing one bond (Figure 2.14 C).  
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Figure 2.14A. FZ 514 (green) binds with GLY 426 A through 
the hydroxyl group in position 17. 
Figure 2.14B. FZ 514 (green) Vs. capecitabine (gold) which 
binds with LYS 431 A.  
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The second set of compounds, triazole containing aromatic amines, exhibited 
general binding affinities involving the hydroxy group on position 17, as well as N3 of the 
triazole ring. In addition, a hydrophobic interaction took place when position 3 was 
substituted with OBn. This trend is the mode of action noticed in FZ 25, FZ 57, FZ 200, 
FZ 300, FZ 313 and FZ 400. Figures 2.15 A-C represent the binding affinities of this class 
of compounds.  
Similarly, the binding affinity of the last set of ligands is different than the aromatic 
amines attached to the triazole ring. The last set of ligands bears either piperidine or 
morpholine, with differing functionality on position 3. In general, the morpholine moiety 
containing a ligand has better binding affinity with two different hydrogen bonds involving 
CYS 424 A through the hydroxy group on position 17 and N3 of the triazole ring on SER 
Figure 2.14 C. FZ 514 (green) Vs. 5-FU (gold) which binds with 
CYS 424A. 
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428 A. While the piperidine containing ligands are not interacting with amino acids in the 
binding pocket through hydrogen bonding, they do bind through the hydrophobic 
interaction.  
Figure 2.15 A. FZ 200 (yellow), which binds with SER 428 A with 
two hydrogen bonds utilizing OH present on position 17 as well as 
N2 of the triazole ring. 
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2.4.3. Result and Discussion of Molecular Modeling with MEK 
The result of the molecular docking conducted on the human mitogen-activated 
protein kinase MEK1 receptor (3PP1) was different than that seen with the RAF receptors. 
In the case of a heterocyclic amine attached to the triazole ring, the estrone part of the 
ligand pumped out of the pocket, while the triazole part was oriented inside the pocket. 
This indicates that only the triazole ring will react with the binding pocket.  Figure 2.16 
shows the orientation of the indole containing ligands in the MEK receptor. On the 
contrary, ligands containing aromatic amines attached to the triazole ring, as well as the 
Piperidine and morpholine containing triazoles, fit in the pocket with different binding 
modes. Figure 2.18A-B represents the binding modes of action in the MEK pocket 
 
Figure 2.15 B. FZ 200 (yellow) VS 5-FU(gold), which binds CYS 
424A utilizing one hydrogen bond. 
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Figure 2.17. FZ 518 inside the MEK receptor. The estrone part is 
oriented outside of the pocket. 
Figure 2.18 A. FZ 550 (pink) Vs. capecitabine (gold) which binds 
through VAL 211 A and PHE 209 A utilizing two hydrogen bonds. 
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2.5. Summary of the mode of action in the selected receptors 
The binding modes in EGFR (1m17) show that the presence of an indole nucleus 
is important in the binding of the ligands to the pocket. This binding is through N2 and N3 
of the triazole ring. It appears that the indole ring can deliver the ligand closer to the pocket, 
to a space that is necessary to form the hydrogen bond. On the contrary, the absence of an 
indole ring changes the trending to a hydrophobic interaction, when the substituent on N1 
of the triazole ring is bearing an aromatic amine. 
Figure 2.18 B. FZ 400 (green) Vs. 5-FU (gold) which binds through 
ARG 234 A utilizing one hydrogen bond through PHE 209 A. The same 
amino acid binds with the designed ligand. 
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Binding modes in the B-Raf Kinase Domain (3prf) showed similar results in 
comparison to 1M17. The presence of an indole nucleus showed a hydrophobic interaction; 
however, there were no hydrogen bonds involved in the binding. Similarly, an aromatic 
amine containing triazoles exhibits a hydrophobic interaction, except in the case of a mild 
polarity on position 3, which results in hydrogen binding with CYS532 B. Alternatively, 
the last set of compounds (3compounds) have a different mode of action. The piperidine 
nucleus-containing compound binds with SER 535 B (the same amino acids bind with 
capecitabine) through the OH existing on position 17 (FZ 552, FZ 600 and FZ 556), while 
the morpholine containing triazole binds with a different amino acid (SER 536 B) utilizing 
N2 on the triazole ring. 
The binding affinities of RAF-1 (3OMV) are different than the binding affinities in 
the B-RAF Kinase Domain (3prf). The presence of an indole ring attached to the triazole 
fragment establishes a hydrogen bond with the hydroxyl group present in position 17 with 
GLY 426 A. The triazole containing aromatic amines, exhibiting general binding affinities, 
involve the hydroxy group on position 17, N3 of the triazole ring, and a hydrophobic 
interaction when position 3 is substituted with OBn. 
The last set of ligands bears either piperidine or morpholine, with different 
functionality on position 3. In general, the morpholine moiety-containing ligand has a 
better binding affinity with two different hydrogen bonds involving CYS 424 A through 
the hydroxy group on position 17 and N3 of the triazole ring SER 428 A. While the 
piperidine-containing ligands are not interacting with amino acids in the binding pocket 
through hydrogen bonding, they do bind through the hydrophobic interaction. 
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The result of the molecular docking conducted on human mitogen-activated protein 
kinase MEK1 receptor (3PP1) was different than that seen with the RAF receptors. In the 
presence of a heterocyclic amine attached to the triazole ring, the estrone part of the ligand 
pump is out of the pocket while the triazole part is oriented inside the pocket. This indicates 
that only the triazole ring reacts with the binding pocket. 
2.6. Conclusion  
The molecular docking process proved its feasibility in terms of drug discovery 
methodologies. In addition, it saves tremendous amounts of time and money on the drug 
discovery process. This process can speculate on the binding affinity energy and express it 
as a consensus score, which eventually represents the small molecule behavior in the 
biological system and the interaction of ligands with molecular targets. In this work, 
molecular modeling was used under consideration of the possibility of pharmacophore 
presence through the 1.2.3-triazole ring utilizing the estrone main skeleton to deliver the 
triazole-bearing ligand to the receptor in silico. The molecular modeling also took into 
consideration the EGFRs starting from upstream and ending with downstream as a known 
overexpression in many cancer diseases, including colorectal cancer (CRC). The whole 
process aimed to discover and synthesize a possible drug that can be used to inhibit the 
signaling pathway observed in CRC.  
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Chapter Three 
Design, Synthesis and biological evaluation of novel estrone -1.4-disubstituted 
triazoles analogs targeting colorectal cancer 
ABSTRACT 
Colorectal cancer is the second death causing disease in the United States when men and 
women considered collectively. Epidermal Growth Factor Receptors (EGFRs) are over 
expressed in cancer cells. Targeting and blocking the downstream signaling could lead to 
cease cell proliferation and division and hence control the spread of the disease. 1,2,3-
Disubstituted triazole as a pharmacophore showed a potency towards many diseases 
including cancer. Estradiols are a class of estrogen naturally occurring compounds and 
they are known for their penetration of the cell, therefore, incorporation of 1.2.3-triazole 
on a carrier such as estradiol could lead to drug discovery. A library of 1.2.3-triazole-
estradiol-based analogs were designed and virtually screened with EGFRs utilizing 
OpenEye® as docking software. Among the designed candidates, fourteen 1,4-
disubstituted triazole analogs of 3-functionalized estradiol were synthesized and 
biologically evaluated. MTT assay conducted on CRC cancer cell line shows cytotoxicity 
behavior for 5 compounds ranging from 3.5 µM for FZ60 to 30 µM for FZ518. 
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3.1. Introduction  
Colorectal cancer is the second death causing disease in the United States when 
men and women considered collectively. Estrogens as a natural product compounds are 
biologically synthesized by the human body through multiple processes starting from 
cholesterol as starting material [15]. Among estrogen class of compounds are estrone and 
estradiol, which are identified  pharmacophores for the estrogen receptors ER [16]. 
Furthermore, many investigations in the estrone-based drug design, have found 
candidates with a high potency and specificity towards cancer cells such as ovarian, 
prostate and breast cancer [17-19]. Among these investigations, Ahmad et al., 2014 
assembled the pharmacophore that is responsible for the cytotoxicity of cucurbitacin D on 
estrone as carrier skeleton [17]. Around these facts, a hypothesis was developed assuming 
that utilizing click chemistry to generate a triazole pharmacophore carried by a steroidal 
skeleton may lead to novel drug candidates for CRC. This hypothesis was packed by 
finding from other data obtained from Solum et al., 2014, in tubulin polymerization 
inhibition as well as cytotoxicity activity utilizing estradiol-triazole moieties [19].  
Many researchers used the same approach to discover new drug candidates; for 
example, a number of steroidal moieties bearing triazole pharmacophore to inhibit human 
CYP17 targeting prostate cancer with IC50 ranging from 50-12000 nM [20]. Another 
example of utilizing the same approach is observed in incorporation of triazole 
pharmacophore on progesterone, another steroidal hormone, on position 11 by Dhyania et 
al., [21, 22]. Molecular docking data described in chapter 2 was used to determine the 
binding modes of the designed library of 800 compounds. The  
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Scheme 3.1. The retrosynthetic analysis of the designed triazole bearing ihibitors. 
 
A library was virtually screened with Epidermal Growth Factor Receptors 
(EGFRs) starting from extracellular domain to downstream signaling pathway. A library 
of hits ranked based on their consensus scoring was obtained and the mode of actions of 
these hits is described in section 2.4.1-2.4.3. The aim of this study is to design, synthesize 
and biologically evaluates a novel estrone-based triazoles targeting colorectal cancer. 
Scheme 3.1 shows the retrosynthetic route of the designed drug candidates. Where 
reaction of estrone (1) with alkylation agents (A) to afford different functionality groups 
at C-3(B). Consequently, reaction with ethynyltrimethylsilane (C) to afford the alkyne 
(D) necessary to react with organic azides (E) to generate the triazole-estradiol final hits 
(F). 
 
 
 
HO
R1O
N
N
N R2 HO
R1O
O
R1O
TMS H
O
HO
R1 = Me, AcO, Bn, H
O
Cl
MeI
BnCl
+
+
+
R2
N3
R2 = x-PhNHCOCH2-
R2 = C5H10NCOCH2
R2 = C4H8ONCOCH2
R2 = C8H5NCOCH2
R2 = TMS-
(1)
(A)
(B) (C)(D)
(E)
(F)
76 
 
3.2. Material and methods 
3.2.1. General material and methods 
  
1H and 13C NMR were spectra were acquired on a Bruker AVANCE-400 MHz NMR 
spectrometer, in deuterated solvents such as CDCl3 using solvent residual peak as the 
internal standard for 1H NMR (δ=7.24 ppm) and CDCl3 (d = 77.16 ppm) for 
13C NMR, with 
the reporting of coupling constants in Hz and the signal multiplicities are reported as singlet 
(s), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), doublet of triplets (dt), 
multiplet (m), or broad (br). HRMS data was obtained using EI ionization on a 
ThermoFinnigan MAT 95 XL mass spectrometer. TLC analysis was performed using pre-
coated silica gel PE sheets. Products were purified via column chromatography using silica 
gel 40–63 lm (230–400 mesh), normal phase preparative TLC plates. TLC plates were 
visualized by ultraviolet at 254 nm. TLC plates were stained by Iodine, Vanillin, and Ceric 
Ammonium Molybdate (CAM) stain. All reagents and solvents were obtained from 
commercial suppliers and used as received. All chemical reactions requiring anhydrous 
conditions were performed with oven-dried glassware under an atmosphere of nitrogen. 
3.2.2 Cytotoxicity Assay: 
The colon cancer cells line HT_29 were seeded in 96-well plate as 5*104 cells/mL 
(100 μL/well). A serial dilution of compounds was added after overnight incubation of the 
cells at 37°C and 5% CO2. DMSO was used as a control (0.1 %). The cells were incubated 
with the synthesized compounds for 48 hrs. After that 15 μL of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) (5 mg/mL PBS) were added to each well and 
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the plates were incubated for another 4 hrs. The formazan crystals were solubilized by 100 
μL acidified SDS solution (10% SDS/0.01 N HCl). The absorbance was measured after 
14 hrs of incubation at 37°C and 5% CO2 at 570 nm by Biotech plate reader. 
3.3. Result and discussion 
The final selected strategy for acquiring the 1,2,3-triazole ring on position 17 of the 
estrone was designed through assembling an alkyne group on the desired position, 
Scheme3.1. [82]. Typically, this reaction is classified as addition reaction to a carbonyl 
group, which requires a harsh condition to achieve. Many alkyne moieties were incorporated 
to the desired position, including propargyl alcohol and phenyl acetylene moieties [83, 84]. 
Additionally, the protection step was aimed to ease the separation step as the tert-
butyldimethylsilyl ethers (OTBS) group increases the lipophilicity of the titled compound 
(2) section 3.5.1. Formation of organic azides was conducted under high caution, as organic 
azides are usually explosive and photosensitive [85] . 
3.3.1. Synthesis of 17α alkynyl estradioils 
 
It is worth to point out that click chemistry reactions only can be conducted on 
terminal alkynes to result in 1,4-disubstetuted triazoles. However, 1,4,5-trisubstetuted 
triazoles were designed as if the click reaction on internal alkynes (phenyl acetylene and 
propargyl alcohol reactions) proceeds; in other words, the design of the phenyl-triazole 
derivatives was performed as compound (III) can be obtained from the click reaction on 
(II) (scheme 3.2); however, this is not possible and hence a proposed retrosynthetic scheme 
was formed Scheme 3.3A-B. 
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Scheme 3.2. the click reaction cannot proceed on internal alkynes; however, the 
result of the inert reaction was considered in the design of novel inhibitors and alternative 
proposed scheme was designed. 
 
Although the majority of the library hits showed that the 1,4-disubstituted triazoles 
have higher binding scoring. However, attempts to synthesize phenyl-triazole derivatives 
were conducted utilizing one pot reaction, by first, generating the 1,4-disubstituted 
triazole in situ and subsequently reaction with phenyl substituent to occupy position five 
of the triazole ring utilizing Pd as a catalyst. Scheme 3.3A. 
Generation of 1,4-disubstituted triazoles was started with the reaction of estrone 
(1) with TBSCl to afford the protected estrone (2), which subsequently was subjected to 
alkyne addition to generate and then cleavage of protecting groups to result in 17α 
substituted estradioils (3) section 3.4. 2. [82-84]. On the other hand, the aromatic amines 
and heterocyclic amines where subjected to acylation reaction utilizing chloroacetyl 
chloride and subsequently convert the resulting α-chloro amides to α-azido amides by the 
reaction with sodium azide.  
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Scheme 3.3A. The retrosynthetic analysis of one pot reaction to afford 1,2,3-trisubstituted 
triazole. 
Scheme 3.3B. The retrosynthetic analysis of preparation of C5’ carbinol triazole. 
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The  proposed scheme for the fully substituted triazole is presented below in 
Scheme 3.3A-B where the substitution with phenyl group can be obtained by the one pot 
reaction [86]. On the other hand, the carbinolic group can be introduced by generation of 
iodoalkyne (G) and then subsequent reaction in a click reaction manner to generate 5-
iodo-1,4-disubstituted triazole (H) and sunsequently introduce a carboxyl group to 
generate compound (I) by reaction with CO2 and finally reduce the carboxyl group with 
proper reducing agent to the corresponding alcohol (J) [87-90]. The strategy for the 
carbinol bearing triazoles must take in consideration the assembly of the N1’ substituent 
later after  
assembling the triazole ring with functionalized C5’, to put it differently it must take in 
consideration alkylation of N1’ of triazole after reducing the carboxyl group to avoid 
reduction of amide [91]. 
 
 
HO
O
1.TBSCl,imidazole, 0ºC
R1 H3.
THF, -78 ºC
4.TBAF, 0ºC
HO
OH R1
R1=TMS,Ph,CH2OH
(1)
2.n-BuLi
(3A)
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Scheme 3.3: Mechanism of nucleophilic addition to carbonyl group. 
 
3.3.2. Synthesis of organic azides 
Molecular modeling design showed diversity in the azides attached to different 
amines. Therefore, a general scheme for the azide preparation starts from the 
chloroaceylation of amines and subsequent azidation utilizing SN2 reaction mechanism. 
Scheme 3.4 shows the general method for preparation of organic azide. chloroaceylation 
of aromatic heterocyclic amines (indole 33%) was obtained in low yield as comparison to 
aromatic amines (e.g. aniline 95%) due to the resonance of the lone pair on the nitrogen 
atom of indole. The chloroacylation of aliphatic heterocyclic amines (morpholine and 
pipridine) was obtained in high yield in comparison to indole, since the lone pair is not in 
resonance in the heterocyclic ring. 
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Scheme 3.4: General method of preparation of organic azides. 
 
3.3.3. Cytotoxicity results 
 
The synthesized compounds showed variable cytotoxic behavior in comparison to the 
standard 5-FU (IC50 17.3 µM). Functionalization of position 3 of the steroidal skeleton 
with non-polar groups (Me, Bn) show no toxicity. On the contrary, polar functional 
groups at C-3 showed ant proliferative cytotoxicity toward HT-29 cell line. In case of the 
presence of OH group in addition to aromatic amine attached to the triazole, the 
cytotoxicity was as follow: FZ60 IC50 3.5 µM, FZ300 IC50 18 µM, FZ 313 IC50 25 µM, 
and FZ 518 IC50 30 µM. alternatively, in presence of OAC group, for example, FZ 200, 
showed IC50 13 µM. 
It is clear that the polarity of position 3 of the steroidal skeleton as well as the ring 
orientation of the aromatic amine attached to the triazole ring at position 17 are 
contributing factors in the cytotoxicity behavior. Table 3.1 shows the IC50 values in 
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comparison to 5-FU in the HT-29 cell line. Figure 3.1 shows FZ 60 in 3MOV binding 
pocket with all hydrogen bonds involved in the binding. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. FZ60 binds with GLY426A utilizing OH group at C17. Another hydrogen 
bonding by utilizing N2 and N3 of the triazole ring with LYS431A and SER428A 
respectively. 
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Table 3.1: The IC50 values in HT-29 of the designed estradiol-triazole derivatives in 
comparison to 5-FU. 
no Compound IC50 C-3 functionality 
Group attached to 
triazole 
1 FZ60 3.5µM OH aniline 
2 FZ200 10 µM OAC aniline 
3 FZ300 18 µM OH p-Anisidine 
4 FZ313 25 µM OH p-toludine 
5 F3518 30 µM OH indole 
6 FZ400 No cytotoxicity Bn p-toludine 
7 FZ57 No cytotoxicity Bn aniline 
8 FZ516 No cytotoxicity Me indole 
9 FZ514 No cytotoxicity AC indole 
10 FZ25 No cytotoxicity Bn No group attached 
11 FZ552 No cytotoxicity Me pipridine 
12 FZ100 No cytotoxicity OH morpholine 
13 FZ600 No cytotoxicity OH pipridine 
14 FZ550 No cytotoxicity AC pipridine 
15 5-FU 17.3 µM - - 
 
3.4. Conclusion 
Fourteen analogs bearing 1.2.3-triazole were chosen for synthesis based on 
their consensus scores. The synthetic strategy of modifications of the steroidal skeleton 
starts from the generation of 17α ethynyl estradiol to obtain an alkyne functionality that 
can be utilized in the click chemistry subsequently through azide coupling. Functionality 
in C5’  of the triazole ring could be achieved by three components click reaction catalyzed 
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by Cu/Pd to obtain a C5’  functionalized with a phenyl ring, or could achieved by 
assembling 5-iodotriazole and convert the C5’  iodotriazole to carbinol, by carboxylation 
then reduction respectively. Estrone was chosen for the modification for two reasons 
mainly, first: estrone is recognized by human body and can penetrate the cell; 
consequently, it can deliver the triazole pharmacophore to targeted receptors and 
secondly, modification of estrone lead to dramatical change in the biological activity, 
which opens the door for drug discovery. Biological evaluation was conducted on the 
novel compounds and showed a fair cytotoxicity in CRC cell lines by MTT assay. 
3.4.1. Future work and Recommendations 
 
               Our study demonstrated the potential of design and synthesis of 1,4-
disubstituted triazol targeting colorectal cancer. Optimization of triazole analogs ring in 
C5′ has the potential to produce and enhance the biological activities, which is highly 
correlated to the polarity and lipophilicity. The later clearly control the orientation of the 
drug inside the binding pocket, which is a contributing factor in the biological activity. 
Further optimization of the biological activity is necessary and would be beneficial to 
start by optimizing the novel analogs FZ60 to enhance the anticancer activity. Focusing 
on the most active analogs at this points is the best strategy and line up with all recent 
approaches in drug design. 
3.5 Experimental section 
3.5.1. 3-OTBS protected estrone (2) 
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HO
O
H
H
H
3.TBSCl,0ºC
2.Imidazole
TBSO
O
H
H
H
100%
1.DMF
(1) (2)  
To a serried solution of Estrone (1.0g, 3.7 mmol) in DMF 18 ml 3.9 eq of 
imidazole and TBSCl 1.5 eq were added. The reaction was left overnight and then 
quenched with ammonium chloride and extracted with ethylacetate 3x. The organic 
layers were collected evaporated and flash column was used to purify the resulting 
compound using hexane: ethylacetate 9:1 yeilded 100% of compound (1). 
3.5.2. 17α ethynyl estradioil (3) 
 
TBSO
O
H
H
H
1.THF -78ºC
3.H TMS
93%
TBSO
OH
H
H
H
TMS
2.TBAFHO
OH
H
H
H
H
(2)
(2A)
(3)
2.t-BuLi
2. K2CO3
O
HO
H
HH
H
(2B)
Si
88%
1. THF
1. MOH
 
To a serried solution of ethynyltrimethylsilane (27.75 mmol) in dry THF (150 ml) 
t-BuLi (27.75 mmol) was added drop wise at -78 °C under Nitrogen. The reaction was 
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stirred for 2hrs under this condition and allowed to reach 0°C. Then 5.55 mmol of estrone 
(2) in 50 mL THF was added drop wise. The reaction was allowed to reach room  
temperature and  after the completion of the reaction it was quenched with saturated 
ammonium chloride at 0°C. The resulting mixture was extracted with ethylacetate 3x . The 
organic layer was combined and washed with brine, dried over Na2SO4 and reduced under 
vaccum. The crude compound (2A) dissolved in 25 mL MeOH and was moved to the next 
step without purification.  K2CO3 (50 mmole) was added in one portion to (2A) for 2h to 
generate (2B) in 93% yield the product was purified by silica gel chromatography 
hexane/ethyl acetate 9:1 – 8:2. Finally (2B) was subjected to the reaction with 2eq of TBAF 
for 8h and after completion of the reaction, the reaction was quenched with ammonium 
cjloride at 0°C   purified through silica gel chromatography hexane/ethyl acetate 9:1 – 8:2 
yielding 93% of the titled compound (3). The product was proved by 1H-13C NMR. 
 
3.5.3.  Ethynyl estradiol-3-methyl ether (Mestranol) (4) 
 
 
To a stirred solution of (3) (1.61 mmol) in DMSO (6.5 ml), 6.44 mmol of KOH 
was added followed by addition of 1.61 mmol of   MeI. The reaction was stirred for 2h 
under nitrogen. After the reaction completion, it was extracted with DCM 3x, washed 
with brine and dried over Na2SO4. The organic solvent was reduced under vaccum. Silica 
HO
OH
H
H
H
H
MeI, KOH
88%
O
OH
H
H
H
H
O
O
H
H
H
H
+DMSO
(3) (4) (4A)
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gel column chromatography (hexane/EtOAC 8:2) was used to purify the mixture to yield 
compound (4) 88%. The product was proved by 1H-13C NMR. 
 
3.5.4. Ethynyl estradiol-3-methyl benzyl ether (5) 
HO
HO
H
HH
H
BnCl,K2CO3,KI  
       60ºC
MeOH
O
HO
H
HH
H
82%
(3)
(5)
 
To a stirred solution of (3) (1.08 mmol) in dry MeOH (0.5 ml) and 6.44 mmol K2CO3 
(1.18mmol) was added as one portion followed by addition of 1.18 mmol of KI. The 
reaction was stirred for 30 min under reflux at 50 °C. After the reaction completion, the 
reaction was extracted with DCM 3x, washed with brine and dried over Na2SO4. The 
organic solvent was reduced under vaccum and silica gel column chromatography 
(hexane/EtOAC 8:2) was used to purify the mixture to yield compound (5) 82%. The 
product was proved by 1H-13C NMR. 
3.5.5. ethynyl estradiol-3-acetate (6) 
 
HO
HO
H
HH
H
AcO
HO
H
HH
H
2-propanol/H2O
Ac2O
NaOH
1h 93%
(3)
(6)
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1.7 mmol of compound (3) dissolved in isopropanol 12.5 mL containing 0.185 g of 
NaOH dissolved in 2.5 mL H2O was stirred and 0.5 mL of acetic anhydride was added 
gradually.  After the reaction completion, the reaction was extracted with DCM 3x, washed 
with brine and dried over Na2SO4. The organic solvent was reduced under vaccum and 
silica gel column chromatography (hexane/EtOAC 8:2) was used to purify the mixture to 
yield compound (6) 82%. The product was proved by 1H-13C NMR. 
3.5.6. 2-chloro-N-(4-methoxyphenyl)acetamide (7) 
 
O
NH2 1.ClCH2COCl
2.DCM, 0ºC
3.Et3N,20h
93% O
HN
O
Cl
(7A) (7)  
To a solution of p-anisidine  (7A)(5.4 mmol) in 10 ml dichloromethane and 
triethylamine (10.75 mmol, 1.5 ml) chloroacetyl chloride (1 mmol ,0.44 ml) was added 
dropwise at 0ºC under nitrogen atmosphere and vigorous stirring. The reaction was then 
allowed to reach room temperature for 20h. After the reaction completion the reaction was 
quenched with ammonium chloride and washed with 20 ml ethyl acetate 3X. the organic 
layers were combined and washed with saturated sodium chloride and dried over sodium 
sulfate anhydrous. The product was purified using silica gel column chromatography 
hexane: ethyl acetate 9:1 to yield 2-chloro-N-phenylacetamide (7) 93%. The product was 
proved by 1H-13C NMR. 
3.5.7. 2-chloro-N-(p-tolyl)acetamide (8) 
 
90 
 
NH2 1.ClCH2COCl
2.DCM, 0ºC
3.Et3N,20h
95%
HN
O
Cl
(8A) (8)  
To a solution of p-toluidine (5.4 mmol) (8A) in 10 ml dichloromethane and 
triethylamine (10.75 mmol, 1.5 ml) chloroacetyl chloride (1 mmol ,0.44 ml) was added 
dropwise at 0ºC under nitrogen atmosphere and vigorous stirring. The reaction was then 
allowed to reach room temperature for 20h. after the reaction completion the reaction was 
quenched with ammonium chloride and washed with 20 ml ethyl acetate 3X. the organic 
layers were combined and washed with saturated sodium chloride and dried over sodium 
sulfate anhydrous. The product was purified using silica gel column chromatography 
hexane: ethyl acetate 9:1 to yield 2-chloro-N-phenylacetamide (8) 95%. The product was 
proved by 1H-13C NMR. 
3.5.8. 2-chloro-N-phenylacetamide (9) 
 
NH2 1.ClCH2COCl
2.DCM, 0ºC
3.Et3N,20h
95%
HN
O
Cl
(9A) (9)  
To a solution of aniline (9A) (51 mmol, 2ml) in 56 ml dichloromethane and 
triethylamine (102 mmol, 14.2 ml) chloroacetyl chloride (1.5 mmol ,6.1ml) was added 
dropwise at 0ºC under nitrogen atmosphere and vigorous stirring. The reaction was then 
allowed to reach room temperature for 20h. after the reaction completion the reaction was 
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quenched with ammonium chloride and washed with 20 ml ethyl acetate 3X. the organic 
layers were combined and washed with saturated sodium chloride and dried over sodium 
sulfate anhydrous. The product was purified using silica gel column chromatography 
hexane: ethyl acetate 9:1 to yield 2-chloro-N-phenylacetamide (9) 98%. The product was 
proved by 1H-13C NMR. 
 
3.5.9. 2-chloro-1-morpholinoethan-1-one (10) 
 
1.ClCH2COCl
2.DCM, 0ºC
3.Et3N,overnight
99%
O
H
N
O
N
O
Cl
(10A) (10)  
To a solution of morpholine (10A) (6.4 mmol, 0.5 ml) dissolved 10 ml 
dichloromethane and triethylamine (1.3 mmol, 1.7 ml) chloroacetyl chloride (9.6 mmol 
,0.76 ml in 2.33ml DCM ) was added dropwise at 0ºC under nitrogen atmosphere and 
vigorous stirring. The reaction was then allowed to reach room temperature for overnight. 
after the reaction completion the reaction was quenched with ammonium chloride and 
washed with 20 ml ethyl acetate 3X. the organic layers were combined and washed with 
saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography hexane: ethyl acetate 9:1 1 to yield 2-
chloro-N-phenylacetamide (10) 99%. The product was proved by 1H-13C NMR. 
3.5.10. 2-chloro-1-(piperidin-1-yl)ethan-1-one (11) 
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1.ClCH2COCl
2.DCM, 0ºC
3.Et3N,overnight
99%
H
N N
O
Cl
(11A) (11)  
To a solution of piperdine (11A) (6 mmol, 0.5 ml) dissolved 18 ml dichloromethane 
and triethylamine (12 mmol, 2 ml) chloroacetyl chloride (8.8 mmol ,0.76) was added 
dropwise at 0ºC under nitrogen atmosphere and vigorous stirring. The reaction was then 
allowed to reach room temperature for overnight. After the reaction completion, the 
reaction was quenched with ammonium chloride and washed with 20 ml ethyl acetate 3X. 
the organic layers were combined and washed with saturated sodium chloride and dried 
over sodium sulfate anhydrous. The product was purified using silica gel column 
chromatography hexane: ethyl acetate 9:1 to yield 2-chloro-N-phenylacetamide (11) 99% 
3.5.11. 2-chloro-1-(1H-indol-1-yl)ethan-1-one (12) 
 
N
O
Cl
H
N 1.DCM
2.Et3N
3.ClCOCH2Cl
24h
33%
(12)(12A)
 
 To a solution of indole (12A) (12.8 mmol, 1.5 g) dissolved 42 ml dichloromethane 
and triethylamine (12 mmol, 0.6 ml) chloroacetyl chloride (7.5 mmol, 1.7 ml) was added 
dropwise at 0ºC under nitrogen atmosphere and vigorous stirring. The reaction was then 
allowed to reach room temperature for 24h. The reaction was quenched with ammonium 
chloride and washed with 20 ml ethyl acetate 3X. The organic layers were combined and 
washed with saturated sodium chloride and dried over sodium sulfate anhydrous. The 
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product was purified using silica gel column chromatography hexane: ethyl acetate 9:1 to 
yield 2-chloro-1-(1H-indol-1-yl)ethan-1-one (12) 33%. The product was proved by 1H-13C 
NMR. 
3.5.12. 2-azido-N-phenylacetamide (7b) 
 
O
HN
O
Cl
1.DMF
2.NaN3
60 ºC
overnight
90% O
HN
O
N3
(7) (7b)  
To a stirred solution of 2-chloro-N-(4-methoxyphenyl)acetamide (7) (1.22 mmol, 
150 mg) in DMF (3ml)  sodium azide  (6.1 mmol ,400 mg) was added under nitrogen 
atmosphere. The reaction was heated gradually until it reaches 60 ºC for overnight. After 
the reaction completion, the reaction was quenched with sodium bicarbonate and washed 
with ethyl acetate (20 ml × 3). The organic layers were combined and washed with 
saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography hexane: ethyl acetate 7:3 to yield 2-
chloro-N-phenylacetamide (7b) 90%. 
3.5.13. 2-azido-N-(p-tolyl)acetamide (8b) 
 
HN
O
Cl
1.DMF
2.NaN3
RT
overnight
88%
HN
O
N3
(8) (8b)  
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 To a stirred solution of 2-chloro-N-(p-tolyl)acetamide (8) (0.55 mmol, 100 mg) in 
DMF (1.5 ml)  sodium azide  (2.8 mmol ,180 mg) was added under nitrogen atmosphere. 
After the reaction completion, the reaction was quenched with sodium bicarbonate and 
washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography hexane: ethyl acetate 7:3 to yield 2-
chloro-N-phenylacetamide (8b) 88%. The product was proved by 1H-13C NMR. 
3.5.14. 2-azido-N-(4-methoxyphenyl)acetamide (9b). 
 
HN
O
Cl
1.DMF
2.NaN3
24h
98%
HN
O
N3
(9)                                           (9b)  
To a stirred solution of 2-chloro-N-phenylacetamide  (9)  divided on two round 
bottom flasks (16.385 mmol, 2.5 g) in DMF (32.75 ml)  sodium azide  (81.94 mmol , 5.3g) 
was added to each flask separately under nitrogen atmosphere. After the reaction 
completion, the reaction was quenched with sodium bicarbonate and washed with ethyl 
acetate (20 ml × 3). The organic layers were combined and washed with saturated sodium 
chloride and dried over sodium sulfate anhydrous. The product was purified using silica 
gel column chromatography hexane: ethyl acetate 7:3 to yield 2-chloro-N-phenylacetamide 
(9b) 98%. The product was proved by 1H-13C NMR. 
 
3.5.15. 2-azido-1-morpholinoethan-1-one (10b) 
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N
O
Cl
1.DMF
2.NaN3
24h
95%
N
O
N3O O
(10)                                             (10b)  
To a stirred solution of 2-chloro-1-morpholinoethan-1-one (10) (8.3 mmol, 1.35 g) 
in DMF (16.6 ml) sodium azide (41.5 mmol, 2.7g) was added under nitrogen atmosphere. 
After the reaction completion, the reaction was quenched with sodium bicarbonate and 
washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed with 
saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography hexane: ethyl acetate 7:3 to yield 2-azido-
1-morpholinoethan-1-one (10b) 95%. The product was proved by 1H-13C NMR. 
3.5.16 2-azido-1-(piperidin-1-yl)ethan-1-one (11b) 
 
N
O
Cl
1.DMF
2.NaN3
24h
96%
N
O
N3
(11)                                            (11b)  
To a stirred solution of 2-chloro-1-(piperidin-1-yl)ethan-1-one (11) (5.8 mmol, 940 
mg) in DMF (11.5 ml) sodium azide (29.2 mmol, 2.0 g) was added under nitrogen 
atmosphere. After the reaction completion, the reaction was quenched with sodium 
bicarbonate and washed with ethyl acetate (20 ml × 3). The organic layers were combined 
and washed with saturated sodium chloride and dried over sodium sulfate anhydrous. The 
product was purified using silica gel column chromatography hexane: ethyl acetate 7:3 to 
yield 2-azido-1-(piperidin-1-yl)ethan-1-one (11b) 96%. The product was proved by 1H-13C 
NMR. 
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3.5.17 2-azido-1-morpholinoethan-1-one (12b) 
 
N
O
Cl
1.DMF
2.NaN3
24h
88%
N
O
N3
(12)                                                 (12b)  
To a stirred solution of 2-chloro-1-(1H-indol-1-yl)ethan-1-one (12) (2.05 mmol, 
300 mg) in DMF (6.2 ml) sodium azide (10.8 mmol, 0.70 g) was added under nitrogen 
atmosphere. The reaction was stirred for 24h and was monitored by TLC. After completion 
of the reaction, the reaction was quenched with sodium bicarbonate and washed with ethyl 
acetate (20 ml × 3) The organic layers were combined and washed with saturated sodium 
chloride and dried over sodium sulfate anhydrous. The product was purified using silica 
gel column chromatography ethyl acetate: hexane 7:3 to yield 2-azido-1-(piperidin-1-
yl)ethan-1-one (12b) 88%. The product was proved by 1H-13C NMR. 
3.5.18. Estra-17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (13)(FZ60) 
  
 
To a stirred solution of alkyne (3) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (9b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
HO
HO
H
HH
H
+
HN
O
N3
CuSO4, sodium ascorbate
t-BuOH/H2O
50ºC
  71%
HO
HO
H
HH
N
N
N
NH
O
(3)                                   (9b)                                                                                (13)
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with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield Estra-
17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (13) 71%.1HNMR (400 MHz, 
Acetone-d6) δ 9.73 (s, 1H), 8.00 (s, 1H), 7.94 (s, 1H), 7.68 – 7.65 (m, 2H), 7.35 – 7.32 (m, 
2H), 7.12 – 7.10 (m, 1H), 7.06 – 7.02 (m, 1H), 6.58 (m, 1H), 6.54 (d, J = 2.6 Hz, 1H), 5.38 
(s, 2H), 2.78 – 2.67 (m, 3H), 2.43 – 1.93 (m, 4H), 1.87 – 1.65 (m, 6H), 0.94 (s, 3H), 0.86  
(m, 2H).13CNMR (101 MHz, Acetone) δ 165.07, 162.99, 155.96, 155.15, 139.55, 138.45, 
132.03, 129.72, 127.01, 124.83, 120.34, 115.98, 113.59, 82.70, 53.41, 48.98, 48.07, 44.51, 
40.68, 38.57, 36.29, 33.83, 31.16, 28.38, 27.30, 24.50, 23.36, 14.94. HRMS Clac. for 
473.2547found 473.25482 
 
3.5.19. Estra-17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (14)(FZ300) 
 
 
To a stirred solution of alkyne (3) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (7b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield Estra-
H
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17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (14) 71%. 1HNMR (400 MHz, 
DMSO-d6) δ 10.25 (s, 1H), 8.83 (s, 1H), 7.74 (d, J = 2.4 Hz, 1H), 7.34 (d, J = 7.9 Hz, 2H), 
6.97 (d, J = 8.0 Hz, 2H), 6.81 (d, J = 8.3 Hz, 1H), 6.34 (m, 1H), 6.29 (d, J = 2.6 Hz, 1H), 
5.15 (s, 2H), 5.01 (s, 1H), 2.60 – 2.49 (m, 2H), 2.24 (m, 1H), 2.08 (m, 3H), 1.82 – 1.60 (m, 
4H), 1.38 – 1.07 (m, 6H), 0.78 (s, 3H), 0.53 (m, 1H).13CNMR (101 MHz, DMSO) δ 
170.27, 164.04, 154.86, 153.95, 137.11, 135.92, 132.66, 130.36, 129.22, 125.95, 124.22, 
119.17, 114.88, 112.64, 81.13, 59.73, 52.09, 47.52, 46.75, 43.16, 37.17, 32.55, 29.26, 
27.20, 26.07, 23.55, 20.41, 14.40. HRMS Calc. for 503.2653. found 503.26514. 
3.5.20. Estra-17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (15)(FZ313) 
 
 
To a stirred solution of alkyne (3) (0.70 mmol) in t-BuOH/H2O (4mL), 
CuSO4 0.1 eq, sodium ascorbate 0.2 eq and azide (8b) (0.88 mmol) was added respectively. 
The reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium 
chloride and washed with ethyl acetate (20 ml × 3). The organic layers were combined and 
washed with saturated sodium chloride and dried over sodium sulfate anhydrous. The 
product was purified using silica gel column chromatography ethyl acetate: hexane 8:2 to 
yield Estra-17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (15) 69 %.1HNMR (400 
MHz, DMSO-d6) δ 10.36 (s, 1H), 9.00 (s, 1H), 7.89 (s, 1H), 7.54 – 7.49 (m, 2H), 6.99 – 
6.92 (m, 2H), 6.90 (d, J = 2.2 Hz, 1H), 6.49 (dd, J = 8.3, 2.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 
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1H), 5.28 (s, 2H), 5.18 (s, 1H),3.70 (s, 3H) 2.78 – 2.67 (m, 3H), 2.43 – 1.93 (m, 4H), 1.87 
– 1.65 (m, 6H), 0.94 (s, 3H), 0.86 (m, 1H), 0.70 – 0.64 (m, 1H).13CNMR (101 MHz, 
DMSO) δ 163.77, 155.47, 154.83, 153.92, 137.12, 131.50, 130.36, 125.96, 124.20, 120.73, 
114.86, 113.94, 112.62, 81.11, 59.74, 55.10, 52.02, 47.51, 46.73, 43.15, 37.13, 32.54, 
29.25, 27.20, 26.05, 23.54, 20.70, 14.39, 14.04. HRMS Calc. for 487.2704. found 
487.27104. 
3.5.21. Estra-17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (16)(FZ518) 
 
 
To a stirred solution of alkyne (3) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (12b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield Estra-
17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (16) 69%.1HNMR (400 MHz, 
DMSO-d6) δ 9.00 (s, 1H), 8.31 (d, J = 7.9 Hz, 1H), 8.02 (s, 1H), 7.97 (s, 1H), 7.67 (d, J = 
7.4 Hz, 1H), 7.38 – 7.31 (m, 2H), 6.99 (s, 1H), 6.88 (d, J = 3.8 Hz, 1H), 6.50 (dd, J = 8.5, 
2.6 Hz, 1H), 6.45 (s, 1H), 6.17 (s, 2H), 2.53 –  2.43 (m, 3H), 2.22 – 1.98 (m, 4H), 1.41 – 
1.16 (m, 6H), 0.96 (s, 3H), 0.84 – 0.68 (m, 2H).13CNMR (101 MHz, DMSO) δ 165.68, 
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154.86, 154.26, 148.57, 137.14, 134.98, 130.37, 130.08, 125.99, 125.67, 124.97, 123.95, 
121.10, 115.73, 114.89, 112.64, 109.42, 81.13, 52.20, 47.58, 43.21, 43.21, 37.23, 32.60, 
29.27, 27.22, 26.10, 23.58, 14.41.HRMS. Cal. for 519.238216 found 519.236662         
  
3.5.22. 3- Omethoxy estra-17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (17)(FZ 
516) 
 
 
To a stirred solution of alkyne (4) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (12b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield 3- 
Omethoxy estra-17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (17) 70%.1HNMR 
(400 MHz, DMSO-d6) δ 8.31 (d, J = 7.9 Hz, 1H), 8.02 (d, J = 3.9 Hz, 1H), 7.96 (s, 1H), 
7.70 – 7.65 (m, 1H), 7.39 – 7.30 (m, 2H), 7.11 (d, J = 8.7 Hz, 1H), 6.88 (d, J = 3.8 Hz, 
1H), 6.65 (dd, J = 8.5, 2.7 Hz, 1H), 6.60 (d, J = 2.9 Hz, 1H), 6.18 (s, 2H), 5.26 (s, 1H) 3.69 
(s, 3H). 2.53 –  2.43 (m, 3H), 2.22 – 1.98 (m, 4H), 1.41 – 1.16 (m, 6H), 0.96 (s, 3H), 0.84 
– 0.68 (m, 2H).13CNMR (101 MHz, DMSO) δ 165.69, 156.96, 154.24, 137.40, 134.96, 
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132.08, 130.07, 126.11, 125.68, 124.96, 124.46, 123.95, 115.72, 113.36, 111.39, 109.41, 
81.10, 54.80, 52.19, 47.55, 46.77, 43.20, 37.19, 32.57, 29.36, 28.21, 27.13, 26.01, 23.57, 
14.39.HRMS. Calc. for 533.253636 found 533.252312. 
3.5.23. 3-Oacetate estra-17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (18)(FZ514) 
 
 
To a stirred solution of alkyne (6) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (12b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield 3-
Oacetate estra-17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (18) 68%.1HNMR 
(400 MHz, Acetone-d6)  δ 8.38 (dd, J = 8.2, 3.5 Hz, 1H), 7.95 – 7.91 (s, 1H), 7.65 (d, J = 
7.4 Hz, 1H), 7.34 (t, J = 9.0 Hz, 1H), 7.22 (d, J = 8.3 Hz, 2H),  6.87 – 6.80 (m, 1H), 6.79 
(s, 2H), 6.21 – 6.13 (m, 1H), 6.17 (s, 2H), 2.53 –  2.43 (m, 3H), 2.24 (s, 3H), 2.22 – 1.98 
(m, 4H), 1.41 – 1.16 (m, 6H), 0.96 (s, 3H), 0.84 – 0.68 (m, 2H).13C NMR (101 MHz, 
Acetone) δ 169.91, 166.02, 155.37, 149.69, 138.85, 138.61, 136.54, 131.38, 127.03, 
126.00, 125.69, 125.00, 122.44, 121.96, 119.62, 117.01, 110.69, 82.73, 60.62, 53.16, 
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49.06, 48.07, 44.62, 40.19, 38.60, 33.82, 28.11, 27.09, 24.54, 21.09, 14.94. HRMS Calc. 
for 561.248732 found 561.247226.          
3.5.24.  Estra-17 1H-1,2,3-triazol-1-yl)-1-(piperidin-1-yl)ethanone (29)(FZ600) 
 
 
To a stirred solution of alkyne (3) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (11b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield Estra-
17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (19) 70%.1HNMR (400 MHz, 
DMSO-d6) δ 8.94 (s, 1H), 7.74 (s, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.48 (dd, J = 8.4, 2.7 Hz, 
1H), 6.43 (d, J = 2.6 Hz, 1H), 5.44 (s, 2H), 5.11 (s, 1H), 3.50 – 3.42 (m, 4H), 2.79 – 2.65 
(m, 2H), 2.12–2.06 (m, 1H),  1.95–1.66 (m,3H), 1.69 – 1.50 (m, 7H), 1.47– 1.16 (m, 6H), 
0.94 (s, 3H), 0.68 (m 1H).13CNMR (101 MHz, DMSO) δ 163.86, 154.82, 153.65, 137.10, 
130.35, 125.88, 124.19, 114.82, 112.58, 81.07, 50.46, 48.50, 47.48, 46.69, 45.20, 43.17, 
42.42, 39.70, 39.56, 39.42, 39.28, 39.15, 39.01, 38.87, 37.04, 32.49, 29.21, 27.18, 26.03, 
25.74, 25.09, 23.79, 23.45, 14.26.HRMS. Calc. for 465.2860. found 465.28653. 
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3.5.25. 3-OAcetate estra-17 1H-1,2,3-triazol-1-yl)-1-(piperidin-1-yl)ethanone 
(20)(Fz550) 
 
 
 
To a stirred solution of alkyne (6) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (11b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield Estra-
17-(1H-1,2,3-triazol-1-yl)-N-phenylacetamide)diol (20) 80%.1HNMR (400 MHz, 
Acetone-d6) δ 7.54 (s, 1H), 7.02 (d, J = 8.5 Hz, 1H), 6.61 – 6.60 (d, 1H), 5.19 (s, 2H), 3.32 
(m, 4H), 2.22 (m, 2H),2.02(s, 3H) 1.98 –1.84 (m, 4H)1.63 – 1.38 (m, 6H), 1.43 – 1.11 (m, 
6H), 0.88 (s, 3H), 0.88 (m, 1H), 0.74 – 0.58 (m, 2H). 13CNMR (101 MHz, Acetone) δ 
169.84, 164.61, 154.79, 149.68, 138.83, 138.59, 127.01, 124.75, 122.44, 119.62, 82.62, 
51.64, 48.97, 47.97, 46.56, 44.66, 43.66, 40.21, 38.49, 33.76, 28.12, 27.12, 26.27, 25.09, 
24.51, 21.08, 14.93. HRMS. Calc. for 507.296. found 507.29702. 
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3.5.26. Estra-17 1H-1,2,3-triazol-1-yl)-1-(morpholen-1-yl)ethanone (26)(FZ100) 
 
 
To a stirred solution of alkyne (3) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (10b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield Estra-
17 1H-1,2,3-triazol-1-yl)-1-(morpholen-1-yl)ethanone (21) 82%.1HNMR (400 MHz, 
DMSO-d6) δ 8.98 (s, 1H), 7.75 (s, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.48 (dd, J = 8.4, 2.7 Hz, 
1H), 6.43 (d, J = 2.6 Hz, 1H), 5.45 (d, J = 2.7 Hz, 2H), 5.13 (s, 1H), 3.67 – 3.47 (m, 6H), 
2.78 – 2.66 (m, 2H), 2.40 – 2.35 (m, 1H), 2.13 – 2.06 (m, 1H), 2.00 – 1.93 (m, 1H), 1.88 – 
1.75 (m, 3H), 1.66 (m, 1H), 1.48 – 1.18 (m, 6H), 0.94 (s, 3H), 0.91 – 0.83 (m, 1H), 0.66 
(m, 1H).13CNMR (101 MHz, DMSO) δ 164.59, 154.84, 153.74, 137.13, 130.35, 125.96, 
124.25, 114.86, 112.62, 81.07, 65.93, 65.83, 50.37, 47.49, 46.73, 44.73, 43.18, 41.86, 
37.08, 32.51, 29.25, 26.06, 23.53, 14.39.HRMS. Calc. for 467.2653. found 467.26496. 
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3.5.27.   3-Obenzyl Estra-17 (1H-1,2,3-triazol-1-yl)-N-phenylacetamide (22)(FZ57) 
 
To a stirred solution of alkyne (5) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 eq, 
sodium ascorbate 0.2 eq and azide (9b) (0.80 mmol) was added respectively. The reaction 
was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride and 
washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed with 
saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield 3-
Obenzyl Estra-17 (1H-1,2,3-triazol-1-yl)-N-phenylacetamide (22) 69%.1H NMR (400 
MHz, Acetone-d6) δ 9.65 (s, 1H), 8.02 (s, 1H), 7.95 (s, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.32 
(t, J = 7.9 Hz, 2H), 7.10 (t, J = 7.4 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 6.58 (dd, J = 8.4, 2.7 
Hz, 1H), 6.53 (d, J = 2.6 Hz, 1H), 5.38 (s, 2H), 2.78 – 2.67 (m, 3H), 2.43 – 1.93 (m, 4H), 
1.87 – 1.65 (m, 6H), 0.94 (s, 3H), 0.86  (m, 2H).13C NMR (151 MHz, Acetone) δ 165.10, 
157.62, 155.16, 139.49, 138.78, 138.65, 133.65, 129.75, 129.26, 128.50, 128.33, 127.13, 
124.90, 124.81, 120.43, 115.53, 113.09, 82.75, 70.27, 53.46, 49.03, 48.09, 44.48, 40.56, 
38.62, 33.85, 29.59, 28.34, 27.24, 24.53, 14.99.HRMS.  Calc. for 563.3017. found 
563.30396. 
 
 
O
HO
H
H
H
H
+
NH
O
N3
CuSO4, sodium ascorbate
t-BuOH/H2O
50ºC
  69% O
HO
H
H
H
N
N
N
NH
O
(5)                                    (9b)                                                                                          (22)
106 
 
3.5.28. 3-Obenzyl Estra-17 (-1H-1,2,3-triazol-1-yl)-N-p-tolylacetamide (23)(FZ400) 
 
  
To a stirred solution of alkyne (5) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (8b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield Obenzyl 
Estra-17 (-1H-1,2,3-triazol-1-yl)-N-p-tolylacetamide (23)(FZ400)70%.1HNMR (400 
MHz, DMSO-d6) δ 10.25 (s, 1H), 8.83 (s, 1H), 7.74 (d, J = 2.4 Hz, 1H), 7.34 (d, J = 7.9 
Hz, 2H), 6.97 (d, J = 8.0 Hz, 2H), 6.81 (d, J = 8.3 Hz, 1H), 6.34 (m, 1H), 6.29 (d, J = 2.6 
Hz, 1H), 5.15 (s, 2H), 5.01 (s, 1H), 2.60 – 2.49 (m, 2H), 2.24 (m, 1H), 2.08 (m, 3H), 1.82 
– 1.60 (m, 4H), 1.38 – 1.07 (m, 6H), 0.78 (s, 3H), 0.53 (m, 1H).13CNMR (101 MHz, 
DMSO) δ 170.27, 164.04, 154.86, 153.95, 137.11, 135.92, 132.66, 130.36, 129.22, 125.95, 
124.22, 119.17, 114.88, 112.64, 81.13, 59.73, 52.09, 47.52, 46.75, 43.16, 37.17, 32.55, 
29.26, 27.20, 26.07, 23.55, 20.41, 14.40.HRMS. Calc. for 577.3173 found 577.31846. 
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3.5.29. 3-metoxy estra-17 1H-1,2,3-triazol-1-yl)-1-(piperidin-1-yl)ethanone 
(24)(FZ552) 
 
 
 
To a stirred solution of alkyne (4) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (11b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield.  3-
metoxy estra-17 1H-1,2,3-triazol-1-yl)-1-(piperidin-1-yl)ethanone (24)(FZ552) 
71%.1HNMR (400 MHz, Chloroform-d) δ 7.63 (s, 1H), 7.13 (d, J = 8.5 Hz, 1H), 6.67 (m, 
1H), 6.60 (d, J = 2.8 Hz, 1H), 5.21 (s, 2H), 3.15 (s, 3H), 3.58 – 3.46 (m, 4H),2.41 – 2.22  
(m, 2H), 1.93 – 1.86 (m, 4H),1.67 – 1.57 (m,6H), 1.43 – 1.25 (m, 6H), 1.04 (s, 3H), 0.90 – 
0.68 (m, 2H).13CNMR (101 MHz, CDCl3) δ 163.20, 157.34, 153.95, 137.99, 132.67, 
126.27, 123.17, 113.71, 111.40, 82.23, 55.18, 51.20, 47.33, 46.44, 43.52, 39.47, 37.83, 
32.92, 29.90, 27.37, 26.29, 25.36, 24.22, 23.48, 19.60, 14.29.HRMS. Calc. for 479.3017. 
found 479.30139. 
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3.5.30. 3-OAcetate estra-17 (1H-1,2,3-triazol-1-yl)-N-phenylacetamide (25)(FZ200) 
 
 
 
  To a stirred solution of alkyne (4) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 
eq, sodium ascorbate 0.2 eq and azide (9b) (0.80 mmol) was added respectively. The 
reaction was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride 
and washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed 
with saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield 
OAcetate estra-17 (1H-1,2,3-triazol-1-yl)-N-phenylacetamide (25)(FZ200).73%.1H NMR 
(400 MHz, Acetone-d6) δ 9.74 (s, 1H), 7.98 (s, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.30 (t, J = 
7.8 Hz, 2H), 7.19 (d, J = 8.5 Hz, 1H), 7.09 (t, J = 7.5 Hz, 1H), 6.83 (d, J = 8.9 Hz, 1H), 
6.78 (s, 1H), 5.40 (s, 2H), 4.41 (s, 1H), 2.24 (s, 3H), 2.15 (m, 4H), 1.95 (m, 4H), 1.36 – 
1.24 (m, 6H), 1.09 (s, 3H), 0.91 – 0.84 (m, 2H).13C NMR (101 MHz, Acetone) δ 170.05, 
165.18, 155.14, 149.66, 139.43, 138.85, 138.63, 129.76, 127.08, 124.97, 122.44, 120.47, 
119.61, 82.78, 53.46, 49.08, 48.05, 44.56, 40.16, 38.63, 33.83, 30.64, 28.09, 27.09, 24.55, 
21.20, 14.65. HRMS. Calc. for 515.2653 found 515.26619. 
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3.5.31. 3-Obenzyl Estra-17 (-1H-1,2,3-triazol) (26) (FZ25) 
 
 
To a stirred solution of alkyne (5) (0.70 mmol) in t-BuOH/H2O (4mL), CuSO4 0.1 eq, 
sodium ascorbate 0.2 eq and azide (13b) (0.80 mmol) was added respectively. The reaction 
was stirred at 50°C for 24h. The reaction was quenched with ammonium chloride and 
washed with ethyl acetate (20 ml × 3). The organic layers were combined and washed with 
saturated sodium chloride and dried over sodium sulfate anhydrous. The product was 
purified using silica gel column chromatography ethyl acetate: hexane 8:2 to yield 3-
Obenzyl Estra-17 (-1H-1,2,3-triazol) (26) (FZ25) 51%.1HNMR (400 MHz, Acetone-d6), 
δ 13.98 (s, 1H), 7.71 (s, 1H), 7.45 (d, J = 6.8 Hz, 2H), 7.37 (d, J = 7.5 Hz, 2H), 7.32 (d, J 
= 7.4 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 6.73 (d, J = 5.7 Hz, 1H), 6.70 (s, 1H) 5.04 (s, 2H), 
2.84–2.61 (m, 2H), 2.52–2.42 (m, 1H), 2.12–1.92 (m, 3H), 1.95–1.66 (m,3H), 1.59–1.27 
(m, 6H), 1.08 (s, 3H), 0.70–0.66 (m,1H). 13CNMR (101 MHz) δ 157.61, 138.74, 138.58, 
133.51, 129.24, 129.19, 128.48, 128.30, 127.08, 115.50, 113.07, 82.63, 70.22, 49.06, 
48.09, 44.49, 40.47, 38.78, 33.89, 29.35, 28.32, 27.14, 24.38, 14.80.HRMS. Calc. for 
430.2489 found 430.24895. 
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Appendix1: consensus scoring of the designed estradiol-triazole library. 
VIDA 
Name 
VIDA 
ID 
PLP Chemgauss3 OEChemscore Screenscore Consensus 
Score 
FZ518_13 2 -73.3132 -86.1279 -51.1893 -178.543 18 
FZ516_6 3 -72.1143 -87.5822 -47.6696 -188.167 26 
FZ514_4 4 -70.4834 -80.0671 -46.3446 -178.962 85 
FZ30_23 5 -58.8637 -93.3865 -46.8942 -165.309 90 
FZ300_25 6 -69.5338 -77.0692 -49.079 -171.085 103 
FZ550_20 7 -69.5338 -77.0692 -49.079 -171.085 107 
FZ600_9 8 -66.8985 -81.6767 -46.2577 -164.832 108 
FZ58 9 -64.1959 -87.6477 -46.5056 -151.585 112 
FZ313_6 10 -69.532 -79.9692 -44.8459 -183.069 118 
FZ25_3 11 -61.4369 -84.4336 -45.8785 -160.62 121 
FZ400_7 12 -70.8689 -76.568 -48.0036 -174.46 121 
FZ520_1 13 -66.066 -76.8503 -48.7326 -173.602 124 
FZ57_73 14 -57.1153 -94.853 -46.9535 -149.389 140 
FZ60_73 15 -57.1153 -94.853 -46.9535 -149.389 144 
FZ552_2 16 -57.2465 -85.7379 -44.8097 -160.104 160 
FZ200_28 17 -59.0869 -79.3166 -48.5955 -154.281 161 
FZ_14 18 -67.1425 -75.8671 -46.6518 -169.39 163 
FZ_50 19 -56.3365 -85.2949 -48.8623 -143.625 170 
FZ512_12 20 -60.4612 -76.0219 -48.6576 -160.667 179 
FZ100_137 21 -65.3973 -81.2972 -45.3846 -147.381 184 
FZ510_25 22 -75.6194 -72.6507 -47.2687 -166.48 189 
FZ624_15 23 -57.9291 -79.969 -45.6426 -156.863 189 
FZ26_10 24 -59.7195 -90.4294 -44.0541 -143.825 199 
FZ319_6 25 -59.4693 -76.588 -47.066 -155.866 200 
FZ108_13 26 -64.7915 -76.7299 -44.6994 -156.325 220 
FZ486_11 27 -69.2441 -75.4287 -43.7607 -177.896 222 
FZ553_151 28 -65.1019 -75.2149 -43.6038 -168.053 249 
FZ10_2 29 -57.1703 -76.3912 -45.4281 -155.503 254 
FZ520_12 30 -67.4681 -77.0751 -41.4539 -167.575 254 
FZ522_12 31 -67.4681 -77.0751 -41.4539 -167.575 256 
FZ9_2 32 -57.1703 -76.3912 -45.4281 -155.503 258 
FZ15_6 33 -56.1002 -76.4524 -44.7101 -155.97 274 
FZ316_16 34 -53.0662 -79.0499 -50.249 -138.496 283 
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FZ27_20 35 -60.4415 -70.7327 -46.1848 -161.25 283 
FZ21_14 36 -56.2403 -75.807 -44.6871 -157.485 284 
FZ534_14 37 -54.479 -85.008 -47.9752 -131.118 286 
FZ423_66 38 -66.3172 -74.5348 -41.9802 -165.136 297 
FZ32_22 39 -56.197 -81.4166 -40.6689 -159.166 307 
FZ187_41 40 -64.1495 -72.274 -44.2427 -151.571 308 
FZ542_4 41 -59.4147 -79.0647 -40.069 -161.998 311 
FZ531_75 42 -52.9113 -81.414 -46.7845 -135.556 311 
FZ425_85 43 -66.7068 -73.8693 -41.8687 -162.384 319 
FZ93_123 44 -57.8861 -80.6319 -42.0667 -141.094 323 
FZ536_8 45 -59.187 -84.4685 -41.9693 -136.725 323 
FZ521_23 46 -65.7554 -71.2773 -42.4269 -162.385 325 
FZ426_8 47 -68.4164 -77.7637 -38.5788 -168.715 338 
FZ189_9 48 -61.6191 -77.2512 -40.4525 -149.913 340 
FZ550_38 49 -59.6025 -74.6821 -42.171 -151.915 342 
FZ301_36 50 -51.2222 -89.8414 -42.3273 -141.647 342 
FZ427_83 51 -55.8815 -82.929 -40.3364 -147.842 345 
FZ344_36 52 -51.2222 -89.8414 -42.3273 -141.647 346 
FZ483_69 53 -55.899 -74.5997 -46.3261 -137.317 348 
FZ6_2 54 -54.6022 -83.6764 -40.2275 -148.306 357 
FZ549_66 55 -58.5657 -71.5585 -42.9567 -151.947 365 
FZ66_8 56 -53.1843 -87.3745 -44.0261 -129.948 368 
FZ313_27 57 -55.7391 -75.6516 -48.2593 -131.303 368 
FZ94_12 58 -61.2277 -64.4345 -44.9911 -158.554 371 
FZ106_14 59 -66.2786 -58.6268 -46.6788 -173.449 372 
FZ535_145 60 -55.8566 -84.2235 -43.4835 -127.312 377 
FZ504_22 61 -63.8195 -61.6453 -47.3391 -152.536 378 
FZ554_14 62 -56.0613 -85.474 -43.3396 -125.749 382 
FZ173_4 63 -64.017 -76.6261 -38.4207 -166.499 390 
FZ512_6 64 -57.0364 -64.373 -50.0677 -145.631 390 
FZ462_15 65 -66.1707 -69.3401 -40.4907 -178.753 390 
FZ332_6 66 -53.339 -74.5492 -46.3364 -135.733 390 
FZ82_1 67 -58.2301 -69.683 -42.8953 -152.573 394 
FZ338_6 68 -53.339 -74.5492 -46.3364 -135.733 394 
FZ422_15 69 -48.1169 -89.8582 -42.7562 -138.058 396 
FZ314_108 70 -57.6926 -67.3758 -46.321 -141.291 396 
FZ317_23 71 -59.3166 -70.6389 -42.2461 -155.071 396 
FZ4 72 -51.0426 -79.6693 -43.1015 -137.74 400 
FZ14_41 73 -52.806 -89.6845 -39.0092 -148.346 405 
FZ551_20 74 -63.7104 -62.6699 -44.2464 -159.173 407 
FZ538_8 75 -54.368 -76.6625 -44.4028 -131.665 416 
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FZ169_9 76 -58.4367 -73.2288 -43.9397 -135.357 419 
FZ3_1 77 -55.2294 -75.0907 -41.0444 -149.581 423 
FZ580_176 78 -60.983 -66.2589 -42.4146 -143.643 452 
FZ374_15 79 -52.6968 -88.3208 -38.6831 -138.7 471 
FZ494_8 80 -49.8408 -84.0711 -42.1401 -129.893 473 
FZ518_15 81 -53.2346 -71.8274 -41.9556 -143.965 479 
FZ307_24 82 -53.7231 -75.3257 -44.4604 -127.181 480 
FZ8 83 -50.1803 -80.6981 -38.8152 -149.937 482 
FZ315_14 84 -50.6828 -71.6078 -45.2301 -136.921 482 
FZ431_41 85 -49.6693 -76.4473 -44.2425 -133.601 483 
FZ456_77 86 -50.8035 -77.5208 -41.9273 -135.479 483 
FZ190_100 87 -62.2544 -70.9163 -41.4225 -136.029 484 
FZ330_24 88 -52.1738 -82.2491 -38.9689 -139.804 484 
FZ529_45 89 -49.7968 -72.0599 -45.0824 -137.278 486 
FZ487_195 90 -49.3031 -70.9413 -44.2193 -146.51 487 
FZ336_24 91 -52.1738 -82.2491 -38.9689 -139.804 488 
FZ327_63 92 -50.7437 -74.5071 -47.1175 -126.058 489 
FZ269_28 93 -51.4848 -63.7386 -44.9218 -155.514 489 
FZ333_63 94 -50.7437 -74.5071 -47.1175 -126.058 491 
FZ477_85 95 -51.7231 -79.7431 -42.7499 -124.466 496 
FZ105_101 96 -52.9786 -85.2176 -36.5323 -145.623 505 
FZ20_8 97 -52.2562 -78.8198 -37.99 -151.175 508 
FZ434_8 98 -50.5304 -77.2186 -40.4328 -137.863 511 
FZ541_71 99 -54.5524 -73.0937 -43.5393 -128.382 513 
FZ117_98 100 -56.9721 -78.0642 -35.4338 -154.786 518 
FZ492_36 101 -49.7351 -83.5182 -38.8129 -139.101 518 
FZ532_18 102 -50.0234 -77.9756 -45.7259 -119.492 523 
FZ577_8 103 -58.5273 -61.1629 -44.1364 -139.034 524 
FZ433_153 104 -51.0308 -81.3242 -39.0244 -135.705 529 
FZ115_97 105 -42.8039 -75.446 -46.2053 -140.204 531 
FZ540_15 106 -54.6099 -74.1463 -42.6208 -125.825 535 
FZ186_77 107 -55.0326 -66.9057 -42.7416 -135.567 539 
FZ17_87 108 -52.4773 -74.3351 -40.1841 -138.681 545 
FZ490_41 109 -52.8837 -76.2838 -39.9146 -135.296 545 
FZ25_11 110 -54.7285 -71.5795 -37.993 -159.322 548 
FZ481_113 111 -59.7038 -69.472 -40.2941 -135.626 548 
FZ48_3 112 -50.9832 -63.66 -53.497 -133.658 549 
FZ318_111 113 -46.4294 -79.5465 -42.2599 -129.909 552 
Erlotinibe 114 -53.0708 -68.6377 -46.0952 -126.378 553 
FZ586_144 115 -46.0233 -72.2362 -45.6576 -134.795 554 
FZ203_4 116 -46.3201 -64.716 -44.2448 -158.286 559 
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FZ172_77 117 -50.1122 -79.3797 -40.3506 -128.252 564 
FZ472_26 118 -53.5756 -70.3264 -41.8316 -134.544 565 
FZ24_18 119 -47.4784 -85.81 -44.8088 -115.236 570 
FZ103_154 120 -54.5255 -74.4842 -37.3395 -146.631 577 
FZ558_79 121 -47.1733 -76.4278 -45.4625 -122.399 579 
FZ79_19 122 -53.7281 -76.8795 -36.1868 -144.081 579 
FZ560_52 123 -53.0893 -71.9352 -44.5425 -121.596 583 
FZ60_10 124 -52.0772 -77.7409 -42.2566 -119.047 583 
FZ58_96 125 -49.2885 -77.0423 -40.9826 -128.437 590 
FZ552_13 126 -54.9522 -74.2293 -44.1723 -116.591 592 
FZ116_11 127 -54.9882 -68.1269 -38.8106 -147.954 594 
FZ432_38 128 -45.7587 -78.4969 -42.2136 -126.422 602 
FZ118_4 129 -61.7841 -63.6335 -38.0071 -153.391 607 
FZ136_15 130 -55.1783 -65.6744 -39.4549 -141.712 610 
FZ171_16 131 -55.85 -66.0513 -39.7641 -137.456 613 
FZ165_15 132 -55.1783 -65.6744 -39.4549 -141.712 614 
FZ480_5 133 -46.7094 -82.357 -38.7838 -134.161 615 
FZ500_42 134 -59.5782 -64.5943 -36.4289 -164.68 618 
FZ127_7 135 -57.105 -73.291 -35.6735 -143.225 624 
FZ559_32 136 -49.2088 -76.3734 -41.9903 -123.103 625 
FZ479_79 137 -52.7706 -70.4433 -43.8667 -122.221 625 
FZ582_39 138 -43.3893 -78.6451 -46.3119 -119.196 628 
FZ498_19 139 -54.2919 -59.3219 -44.6215 -132.29 628 
5-FU 140 -55.5727 -54.8646 -43.1139 -141.268 630 
FZ257_23 141 -47.5053 -64.0215 -41.1439 -157.818 630 
FZ513_39 142 -50.4467 -63.961 -42.5521 -137.282 630 
FZ148_26 143 -54.4994 -63.4126 -40.7375 -138.303 633 
FZ509_90 144 -44.0762 -71.5874 -46.0283 -128.587 639 
FZ463_52 145 -46.8705 -65.7609 -42.4497 -141.165 639 
FZ380_8 146 -48.7137 -74.9015 -43.1453 -121.23 639 
FZ36_19 147 -47.4472 -82.5125 -41.1931 -118.846 641 
FZ430_76 148 -46.9413 -76.2327 -39.5431 -134.169 646 
FZ72_9 149 -54.1929 -70.08 -38.7277 -136.849 647 
FZ428_16 150 -51.6182 -76.6126 -42.3294 -115.193 651 
FZ81_68 151 -56.7351 -70.6795 -35.6215 -145.728 654 
FZ263_26 152 -47.6572 -60.1107 -48.6035 -130.361 660 
FZ533_46 153 -44.9673 -74.258 -45.8021 -119.869 662 
FZ459_54 154 -53.3378 -73.5966 -35.5733 -145.256 663 
FZ561_25 155 -44.7079 -77.0534 -41.667 -125.842 666 
FZ168_15 156 -48.6946 -70.8621 -42.0445 -127.253 667 
FZ563_15 157 -44.882 -77.9197 -41.2912 -124.29 667 
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FZ41 158 -43.727 -70.1728 -45.7686 -129.336 668 
FZ579_15 159 -60.4661 -68.7032 -33.7143 -157.689 669 
FZ392_26 160 -49.6535 -77.7823 -40.4742 -118.524 670 
FZ16_37 161 -48.8529 -82.465 -38.8858 -121.854 671 
FZ458_2 162 -43.2067 -79.8468 -46.5486 -114.331 671 
FZ129_68 163 -39.8432 -78.3691 -39.005 -142.602 678 
FZ562_179 164 -46.7052 -71.8105 -43.5114 -123.181 680 
FZ11_1 165 -49.3853 -76.999 -37.2774 -133.771 682 
FZ130_1 166 -48.4138 -62.6614 -41.3671 -142.935 682 
FZ474_22 167 -47.4474 -73.2447 -39.311 -134.442 689 
FZ22_3 168 -48.9253 -76.5025 -39.5064 -122.791 697 
FZ360_105 169 -45.17 -85.4817 -37.4929 -128.109 701 
FZ91_54 170 -41.6573 -79.604 -42.0886 -122.3 704 
FZ468_16 171 -53.864 -51.8196 -43.8364 -135.199 717 
FZ275_14 172 -55.7727 -55.7709 -42.2779 -130.069 720 
FZ515_62 173 -55.8525 -49.9883 -40.4879 -151.544 721 
FZ429_54 174 -45.0877 -72.1443 -47.5132 -113.622 725 
FZ133_126 175 -39.9426 -80.3338 -43.9071 -115.79 734 
FZ510_38 176 -51.1832 -62.0726 -45.8952 -117.912 734 
FZ162_126 177 -39.9426 -80.3338 -43.9071 -115.79 736 
FZ493_54 178 -46.6011 -64.8241 -44.4203 -123.45 737 
FZ489_82 179 -48.0442 -65.203 -44.8804 -119.332 740 
FZ460_14 180 -42.0548 -69.179 -42.3889 -134.087 741 
FZ567 181 -56.3761 -57.7373 -41.7274 -125.975 742 
FZ188_18 182 -44.1373 -63.2861 -44.2957 -132.449 747 
FZ322_26 183 -59.4378 -68.8417 -34.8685 -133.792 749 
FZ475_178 184 -48.24 -71.1915 -39.0567 -128.305 749 
FZ23_19 185 -47.0728 -71.4721 -39.107 -129.688 751 
FZ537_11 186 -52.5568 -65.8534 -38.4068 -131.63 764 
FZ457_166 187 -48.7491 -64.2757 -41.351 -126.534 766 
FZ356_7 188 -49.2912 -65.8328 -42.4211 -119.688 766 
FZ83_55 189 -52.6777 -66.2751 -34.0063 -151.538 780 
oxaliplatine 190 -46.3484 -75.9761 -40.3616 -116.602 782 
FZ329_10 191 -53.3589 -62.8697 -39.793 -124.057 782 
FZ335_10 192 -53.3589 -62.8697 -39.793 -124.057 786 
FZ585_3 193 -50.9504 -76.7475 -36.765 -119.473 791 
FZ439_113 194 -44.5164 -75.9586 -35.0554 -142.352 791 
FZ35_38 195 -47.9601 -73.1731 -36.3992 -133.092 792 
FZ530 196 -44.9604 -63.1227 -39.4025 -140.395 805 
FZ470_11 197 -43.5045 -64.301 -39.0462 -145.459 810 
FZ469_181 198 -49.6557 -58.3445 -40.8798 -130.489 811 
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ligand_cape 199 -42.2222 -76.7647 -44.842 -107.74 814 
FZ575_4 200 -48.519 -60.7935 -38.8183 -137.05 818 
FZ584_46 201 -51.0159 -63.1794 -41.9883 -116.8 823 
FZ227_6 202 -44.8917 -61.439 -40.677 -135.149 825 
FZ34_17 203 -48.2722 -73.935 -41.5231 -109.021 831 
FZ80_14 204 -40.4293 -72.0242 -37.9366 -138.592 837 
FZ455_92 205 -49.486 -67.5978 -36.9827 -129.388 841 
FZ267_38 206 -44.6439 -56.0757 -41.1159 -140.89 845 
FZ438_11 207 -51.9036 -65.9592 -40.0229 -115.314 846 
FZ326_21 208 -50.5792 -65.9952 -39.9352 -116.425 850 
FZ416_28 209 -43.893 -71.5772 -43.6843 -112.854 852 
FZ5_2 210 -45.4403 -80.1369 -36.0777 -118.914 852 
FZ55_2 211 -47.8711 -56.4229 -38.958 -138.697 862 
FZ408_23 212 -36.8364 -84.0451 -37.6048 -123.357 865 
FZ453_196 213 -46.521 -68.729 -38.1936 -125.349 873 
FZ145_77 214 -47.7712 -71.3023 -33.508 -136.944 878 
FZ583_25 215 -43.792 -79.2503 -38.6241 -114.622 879 
FZ514_50 216 -48.0719 -60.4508 -37.4501 -136.997 880 
FZ128_26 217 -38.7313 -71.2069 -37.0844 -141.232 881 
FZ237_4 218 -39.2417 -59.2067 -39.9151 -147.569 882 
FZ478_7 219 -41.1512 -77.1592 -40.6945 -111.525 884 
FZ516_28 220 -45.8452 -64.662 -39.4623 -124.047 885 
FZ239_4 221 -39.2417 -59.2067 -39.9151 -147.569 886 
FZ328_9 222 -46.2232 -77.3189 -38.7114 -109.934 891 
FZ71_109 223 -48.5416 -62.7043 -36.828 -133.315 894 
FZ517_106 224 -45.487 -64.0227 -41.8861 -117.303 894 
FZ334_9 225 -46.2232 -77.3189 -38.7114 -109.934 895 
FZ325_123 226 -57.4422 -65.8603 -33.834 -123.454 898 
FZ221_1 227 -51.4395 -57.0398 -39.0556 -124.826 901 
FZ62_52 228 -46.7179 -70.8055 -39.5216 -113.813 907 
FZ144_24 229 -44.1647 -52.2494 -46.2223 -122.891 908 
FZ546_7 230 -50.0063 -58.928 -38.1361 -128.62 908 
FZ406_31 231 -35.6517 -84.4236 -35.9731 -124.157 908 
FZ289_13 232 -48.3987 -58.0493 -38.9847 -127.809 915 
FZ454_85 233 -44.6444 -70.073 -37.9187 -123.129 926 
FZ471_54 234 -47.3357 -62.6253 -39.8536 -118.801 927 
FZ331_78 235 -44.4897 -75.5143 -39.1211 -110.934 929 
FZ337_78 236 -44.4897 -75.5143 -39.1211 -110.934 933 
FZ528_4 237 -43.4562 -72.1116 -38.4684 -118.61 941 
FZ149_108 238 -50.0326 -65.7149 -30.5995 -142.279 945 
FZ28_14 239 -44.9504 -71.4026 -41.8688 -102.936 945 
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FZ170_13 240 -47.5649 -43.25 -45.7437 -122.15 947 
FZ68_16 241 -52.1429 -58.9173 -33.0097 -141.56 952 
FZ1_2 242 -44.8158 -77.6807 -34.6806 -117.142 959 
FZ508_88 243 -34.5897 -74.4449 -44.8138 -105.298 959 
FZ295_6 244 -41.9537 -57.8144 -37.5147 -145.772 967 
FZ245_1 245 -47.002 -55.8539 -39.8472 -122.438 973 
FZ40_25 246 -31.9322 -63.5351 -45.0871 -120.501 974 
FZ409_153 247 -41.8659 -81.9202 -33.1834 -122.103 978 
FZ543_33 248 -46.7278 -49.8442 -40.4285 -127.077 986 
FZ7_3 249 -45.1929 -68.7474 -33.156 -134.399 989 
FZ440_6 250 -41.0932 -66.7045 -42.3877 -109.687 998 
FZ209_3 251 -38.2045 -60.4962 -42.7609 -118.074 1001 
FZ445_190 252 -50.3296 -50.4866 -35.6983 -138.543 1002 
FZ539_40 253 -46.3987 -48.4243 -42.5667 -119.421 1006 
FZ281_24 254 -44.8991 -67.7505 -38.8118 -113.334 1011 
FZ294_176 255 -46.2614 -52.8373 -38.7804 -127.605 1016 
FZ410_32 256 -37.3808 -74.172 -37.09 -121.037 1017 
FZ321_47 257 -52.9849 -68.699 -33.2602 -116.186 1025 
FZ233_22 258 -45.7985 -54.3489 -41.0509 -117.177 1025 
FZ525_16 259 -36.6747 -73.9267 -39.5976 -111.313 1034 
FZ215_14 260 -37.8774 -66.4134 -39.3351 -117.686 1039 
FZ225_28 261 -37.0705 -57.3343 -40.3444 -127.589 1041 
FZ197_9 262 -47.8068 -56.9415 -41.362 -109.836 1044 
FZ568_37 263 -42.695 -55.9584 -41.127 -119.199 1045 
FZ107_44 264 -46.9371 -65.5777 -29.4264 -136.896 1052 
FZ95_9 265 -36.521 -69.1691 -34.7177 -132.274 1063 
FZ544_13 266 -45.9768 -58.0994 -39.3196 -114.409 1073 
FZ420_20 267 -31.1817 -83.1956 -35.5684 -115.818 1080 
FZ131_2 268 -32.7742 -65.155 -35.8651 -136.779 1086 
FZ261_9 269 -43.211 -50.5039 -39.1078 -126.792 1089 
FZ384_41 270 -32.5393 -82.1186 -35.3548 -115.019 1092 
FZ312_16 271 -44.9723 -53.5297 -35.8187 -129.863 1102 
FZ251_4 272 -37.2004 -54.6575 -36.1711 -141.295 1107 
FZ466_27 273 -29.7377 -74.0284 -35.7165 -125.21 1107 
FZ59 274 -41.1157 -60.8047 -34.4636 -131.859 1114 
FZ496_32 275 -35.8217 -69.9758 -34.6484 -125.066 1114 
FZ524 276 -38.6544 -75.2374 -37.1257 -107.925 1114 
FZ526 277 -39.6189 -70.9901 -35.4773 -116.637 1114 
FZ573_13 278 -45.8242 -57.7967 -38.2529 -115.352 1117 
FZ396_41 279 -36.2193 -77.0613 -35.937 -109.848 1121 
FZ398_22 280 -46.5019 -63.6208 -35.4463 -114.984 1121 
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FZ65_110 281 -44.9259 -64.5173 -36.8888 -111.894 1122 
FZ436 282 -42.568 -61.3442 -39.7154 -109.809 1130 
FZ507_123 283 -30.6159 -73.817 -41.5958 -100.495 1131 
FZ473_17 284 -48.488 -69.6347 -27.1173 -121.929 1131 
FZ547_65 285 -44.0195 -61.1269 -37.6134 -114.76 1140 
FZ291_36 286 -45.2656 -52.1485 -39.864 -113.303 1140 
FZ397_150 287 -41.9164 -71.1072 -36.1984 -109.538 1143 
FZ378_4 288 -44.8379 -62.8356 -34.9532 -117.665 1144 
FZ348_118 289 -44.624 -57.3338 -33.5246 -130.256 1150 
FZ249_8 290 -34.0012 -55.8967 -37.9615 -132.844 1152 
FZ366_118 291 -44.624 -57.3338 -33.5246 -130.256 1154 
FZ147_70 292 -39.4635 -45.9821 -41.0912 -122.926 1156 
FZ282_11 293 -45.0899 -47.1925 -42.8319 -104.975 1165 
FZ372_20 294 -38.4698 -75.7592 -32.5807 -116.223 1166 
FZ320_192 295 -51.622 -66.9011 -31.4056 -110.304 1168 
FZ370_36 296 -37.2021 -73.2502 -32.0719 -122.049 1171 
FZ506_19 297 -39.328 -53.2074 -43.7437 -105.812 1174 
FZ362_73 298 -34.3053 -77.446 -33.6488 -113.233 1178 
FZ154_11 299 -54.1293 -43.4159 -40.2917 -99.7111 1180 
FZ135_93 300 -43.6698 -50.3894 -38.3547 -121.264 1181 
FZ140_15 301 -42.4516 -47.7492 -39.0372 -121.794 1182 
FZ164_93 302 -43.6698 -50.3894 -38.3547 -121.264 1185 
FZ574_62 303 -43.1815 -52.8051 -38.2518 -118.494 1190 
FZ499_135 304 -31.5581 -69.7833 -35.6043 -121.224 1190 
FZ349_43 305 -43.2044 -54.0016 -33.6422 -131.62 1194 
FZ414_66 306 -36.8869 -70.0233 -37.5427 -106.436 1198 
FZ367_43 307 -43.2044 -54.0016 -33.6422 -131.62 1198 
FZ123_40 308 -41.1568 -45.6667 -40.5258 -117.871 1199 
FZ578_42 309 -46.9812 -37.284 -40.8833 -113.493 1199 
FZ576_23 310 -35.12 -67.3973 -37.894 -110.63 1203 
FZ255_16 311 -34.8723 -46.8517 -42.7693 -115.326 1221 
FZ56 312 -39.5071 -58.2274 -33.2117 -130.226 1223 
FZ297_79 313 -31.477 -82.9266 -32.8528 -110.353 1228 
FZ421_119 314 -37.6103 -66.6822 -34.9369 -114.19 1230 
FZ324_31 315 -43.3725 -75.7399 -28.3504 -112.088 1230 
FZ340_79 316 -31.477 -82.9266 -32.8528 -110.353 1232 
FZ214_57 317 -32.6035 -63.7053 -33.1949 -131.328 1234 
FZ305_5 318 -41.4709 -62.3352 -38.2902 -103.286 1234 
FZ548_3 319 -42.2487 -58.5106 -36.0727 -114.784 1237 
FZ352_71 320 -43.4798 -51.7231 -37.5739 -116.105 1239 
FZ43_3 321 -44.4734 -51.4384 -41.4677 -97.801 1240 
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FZ44 322 -44.4734 -51.4384 -41.4677 -97.801 1241 
FZ13_3 323 -34.2362 -83.2646 -31.2292 -107.938 1243 
FZ461_31 324 -38.4204 -67.0331 -27.4475 -127.588 1243 
FZ45 325 -44.4734 -51.4384 -41.4677 -97.801 1245 
FZ382_28 326 -33.2015 -69.5455 -35.4399 -114.359 1246 
FZ435_28 327 -33.71 -61.6696 -38.5278 -112.592 1253 
FZ119_98 328 -30.8457 -69.7841 -36.3863 -112.909 1258 
FZ31_2 329 -39.8396 -69.4792 -34.1183 -108.787 1259 
FZ19_2 330 -35.1371 -71.1997 -36.4842 -101.127 1261 
FZ311_25 331 -37.3277 -60.2544 -39.9132 -98.2437 1264 
FZ78_1 332 -35.203 -51.5818 -42.7872 -104.121 1267 
FZ142_28 333 -35.3372 -50.4499 -37.182 -124.272 1271 
FZ273_60 334 -39.5571 -55.3043 -33.656 -124.621 1273 
FZ160_28 335 -35.3372 -50.4499 -37.182 -124.272 1275 
FZ207_7 336 -34.6604 -48.7488 -37.8323 -125.081 1276 
FZ571_13 337 -41.0405 -51.0419 -38.3534 -114.409 1279 
FZ92_25 338 -31.8874 -66.4673 -35.6996 -113.748 1280 
FZ134_84 339 -40.8923 -64.6984 -31.15 -117.719 1284 
FZ446 340 -32.3981 -61.0569 -39.65 -104.924 1287 
FZ163_84 341 -40.8923 -64.6984 -31.15 -117.719 1288 
FZ183_7 342 -38.0499 -54.2062 -35.0438 -121.597 1289 
FZ309_44 343 -37.5113 -60.038 -38.5923 -102.856 1291 
FZ231_1 344 -44.3101 -50.2817 -33.8257 -122.446 1293 
FZ156_10 345 -44.7208 -54.7835 -33.8806 -115.047 1296 
FZ293_13 346 -44.5482 -45.4263 -37.7746 -114.979 1298 
FZ195_5 347 -42.434 -49.553 -34.703 -121.559 1312 
FZ386_23 348 -25.9926 -78.993 -31.9583 -112.629 1313 
FZ124_1 349 -44.7944 -41.8839 -33.8739 -124.996 1319 
FZ212_58 350 -40.1901 -29.285 -39.4533 -118.005 1325 
FZ418_39 351 -31.3408 -75.8692 -33.0012 -108.016 1326 
FZ444 352 -39.6729 -51.5869 -37.4587 -113.089 1328 
FZ152_8 353 -40.3345 -44.3947 -36.9684 -119.419 1329 
FZ146_43 354 -43.1999 -51.7144 -31.7918 -124.85 1330 
FZ137_145 355 -32.8998 -65.8813 -29.5069 -122.593 1342 
FZ185_9 356 -35.3525 -48.7122 -37.3385 -118.163 1343 
FZ166_145 357 -32.8998 -65.8813 -29.5069 -122.593 1344 
FZ70_15 358 -31.832 -58.8537 -33.628 -122.425 1357 
FZ57_97 359 -36.5682 -60.0324 -37.122 -101.644 1361 
FZ412_76 360 -39.4392 -53.4916 -34.5425 -115.576 1361 
FZ303_86 361 -36.3366 -61.6552 -36.0036 -102.721 1363 
FZ256_59 362 -26.7682 -61.2824 -34.7709 -119.826 1363 
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FZ104_19 363 -25.3263 -71.0893 -38.0498 -97.1249 1364 
FZ114_3 364 -41.509 -51.0122 -37.1443 -108.022 1364 
FZ394_54 365 -30.4171 -77.6759 -30.495 -104.926 1368 
FZ566_62 366 -37.782 -40.3939 -38.5228 -116.174 1370 
FZ179_2 367 -39.1212 -47.9954 -35.9169 -116.454 1371 
FZ223_23 368 -28.9696 -61.5643 -34.7574 -116.663 1373 
FZ90_27 369 -45.9229 -53.0118 -34.6331 -102.03 1379 
FZ201_6 370 -31.5145 -60.0804 -33.7628 -117.975 1382 
FZ177_2 371 -33.235 -57.9382 -34.667 -116.024 1384 
FZ226_163 372 -23.9617 -62.421 -33.4994 -123.925 1384 
FZ402_51 373 -35.2015 -65.916 -34.2301 -99.9832 1393 
FZ379_1 374 -39.7761 -54.3377 -29.3066 -122.84 1395 
FZ306_161 375 -41.1411 -58.4108 -35.3753 -98.2495 1398 
FZ390_65 376 -37.7577 -58.3009 -36.3313 -97.1333 1419 
FZ495_12 377 -36.8595 -43.9055 -38.87 -107.461 1430 
FZ194_45 378 -33.9292 -37.4858 -38.5707 -116.12 1432 
FZ211_22 379 -28.4449 -60.8023 -35.4385 -111.068 1432 
FZ102_1 380 -40.4049 -53.5851 -33.7121 -109.838 1433 
FZ385_150 381 -36.6268 -69.0918 -28.2152 -107.47 1439 
FZ202_55 382 -20.2418 -66.1502 -29.2334 -124.076 1442 
FZ373_187 383 -34.897 -73.7263 -27.3177 -102.319 1443 
FZ143_175 384 -34.8621 -38.1469 -38.4302 -113.615 1446 
FZ161_175 385 -34.8621 -38.1469 -38.4302 -113.615 1450 
FZ76_1 386 -44.2702 -37.823 -38.3419 -98.1844 1456 
FZ238_151 387 -19.4303 -64.371 -28.2002 -126.621 1465 
FZ565_11 388 -25.4717 -59.723 -36.5024 -107.512 1466 
FZ354_12 389 -37.5993 -59.944 -35.5053 -87.9659 1467 
FZ265_74 390 -26.9817 -60.0747 -34.2515 -113.342 1470 
FZ393_114 391 -45.8693 -33.3426 -38.1086 -94.8204 1474 
FZ302_134 392 -39.593 -48.3383 -32.9655 -115.094 1476 
FZ465_54 393 -33.2367 -58.5659 -35.2568 -99.8413 1482 
FZ350_57 394 -40.9095 -53.0699 -34.6978 -97.7567 1483 
FZ247_19 395 -18.8427 -56.925 -35.7371 -115.427 1491 
FZ369_111 396 -30.7655 -49.584 -40.9313 -88.6669 1493 
FZ417_112 397 -33.3354 -58.0276 -34.2635 -104.258 1495 
FZ110_10 398 -36.9814 -41.3916 -34.0999 -117.33 1496 
FZ413_191 399 -26.6037 -67.0269 -34.9639 -89.9041 1514 
FZ285_22 400 -33.3566 -44.1744 -36.2143 -111.564 1514 
FZ497_64 401 -35.6762 -42.1455 -36.8534 -107.752 1516 
FZ63_55 402 -33.1308 -48.9748 -38.8542 -92.607 1518 
FZ415_183 403 -32.8555 -58.234 -31.4165 -112.824 1518 
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FZ304_93 404 -33.1311 -43.261 -39.1198 -97.2842 1527 
FZ368_57 405 -34.1671 -54.311 -36.954 -87.987 1529 
FZ564_70 406 -31.6784 -53.2595 -35.3281 -104.364 1530 
FZ485_62 407 -27.0591 -54.1653 -31.7661 -119.805 1530 
FZ268_177 408 -25.9117 -55.0753 -32.2721 -118.589 1535 
FZ151_44 409 -31.6917 -50.6284 -37.3963 -98.4155 1538 
FZ347_185 410 -27.4368 -63.7684 -33.1669 -98.9506 1556 
FZ365_185 411 -27.4368 -63.7684 -33.1669 -98.9506 1560 
FZ252_134 412 -35.0592 -34.5236 -38.998 -97.5306 1562 
FZ235_18 413 -23.4838 -59.3654 -34.3259 -104.44 1571 
FZ388_74 414 -34.1064 -56.422 -30.7645 -108.175 1572 
FZ346_155 415 -35.3077 -51.784 -32.7539 -107.331 1573 
FZ355_29 416 -34.3752 -53.585 -29.7976 -111.848 1576 
FZ442_37 417 -21.0116 -59.7734 -36.4612 -94.9385 1580 
FZ219_2 418 -38.6289 -45.9491 -32.3028 -110.472 1581 
FZ276_12 419 -44.0935 -37.3454 -33.635 -101.953 1582 
FZ310_99 420 -24.0543 -67.9188 -33.4186 -89.621 1583 
FZ74_2 421 -35.8625 -42.7286 -38.1449 -87.1284 1587 
FZ199_24 422 -24.2361 -52.9606 -35.3747 -106.553 1593 
FZ61_67 423 -29.7047 -48.0374 -35.86 -105.102 1593 
FZ400_2 424 -41.6797 -59.4722 -23.8943 -96.2511 1597 
FZ505_186 425 -25.8798 -55.2611 -32.6693 -112.423 1599 
FZ403_44 426 -35.6221 -55.5452 -25.7326 -110.559 1601 
FZ253_62 427 -21.5251 -55.7045 -35.096 -104.243 1604 
FZ200_25 428 -33.9235 -27.2133 -35.0726 -113.328 1609 
FZ286_193 429 -37.4824 -49.7306 -32.2972 -102.556 1610 
FZ351_118 430 -29.7458 -58.8799 -33.8371 -89.1292 1624 
FZ411_1 431 -29.7871 -56.0346 -34.8533 -87.1611 1632 
FZ570_40 432 -32.8219 -45.3731 -36.4407 -92.5546 1637 
FZ98_33 433 -32.5791 -51.7952 -30.4359 -108.427 1645 
FZ46_6 434 -31.5969 -46.8411 -33.4675 -105.912 1656 
FZ77_16 435 -28.0873 -51.6949 -33.8984 -99.8702 1658 
FZ49_7 436 -31.6339 -46.6503 -34.3255 -98.8495 1666 
FZ126_1 437 -29.2737 -52.6074 -29.0805 -111.993 1667 
FZ50_7 438 -31.6339 -46.6503 -34.3255 -98.8495 1668 
FZ222_120 439 28.9789 -56.1568 -39.1981 -54.9358 1670 
FZ51 440 -31.6339 -46.6503 -34.3255 -98.8495 1670 
FZ101_63 441 -38.999 -37.8429 -26.4664 -114.636 1671 
FZ100_1 442 -29.1862 -48.0991 -31.9717 -111.393 1671 
FZ437_25 443 -21.3135 -58.7727 -33.4733 -97.309 1674 
FZ243_9 444 -34.9253 -48.2624 -29.755 -105.664 1676 
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FZ353_172 445 -23.8071 -62.0729 -33.4275 -84.0948 1677 
FZ401_187 446 -25.7342 -59.8765 -33.2931 -86.5069 1683 
FZ174_73 447 -33.3242 -46.7217 -33.7986 -95.7373 1685 
FZ125_30 448 -27.2786 -49.2021 -32.014 -110.072 1691 
FZ75_48 449 -23.5351 -34.8028 -39.5657 -91.0807 1691 
FZ491_87 450 -27.7122 -46.2172 -36.7221 -89.6014 1691 
FZ361_176 451 -22.0287 -62.8178 -32.2173 -88.067 1703 
FZ208_129 452 -32.7053 -42.0095 -30.7957 -111.311 1704 
FZ181_24 453 -30.5609 -45.9342 -32.7536 -106.472 1705 
FZ175_30 454 -28.642 -53.2471 -30.3041 -102.73 1709 
FZ205_67 455 -26.8526 -36.8895 -34.6892 -108.888 1711 
FZ184_170 456 -27.4163 -57.759 -29.5101 -98.6405 1712 
FZ283_13 457 -40.6989 -42.0248 -31.109 -95.5748 1712 
FZ358_64 458 -29.9578 -56.7276 -26.9154 -101.717 1716 
FZ279_19 459 -27.665 -52.6355 -33.3497 -92.1784 1721 
FZ502_57 460 -30.312 -48.2263 -34.9679 -83.7578 1721 
FZ113_3 461 -30.2127 -51.8767 -24.3417 -110.521 1722 
FZ111_73 462 -34.2144 -32.853 -31.3524 -110.774 1724 
FZ377_99 463 -19.0043 -63.9901 -32.3793 -80.2572 1724 
FZ89_124 464 -24.4164 -58.5383 -27.5954 -101.643 1734 
FZ389_166 465 -23.6352 -61.7273 -31.2712 -82.1809 1737 
FZ391_3 466 -28.8572 -58.8969 -28.2389 -91.7048 1742 
FZ345_88 467 -28.4723 -43.1094 -35.9023 -85.9025 1744 
FZ176_23 468 -32.2155 -51.13 -27.3868 -101.379 1747 
FZ363_88 469 -28.4723 -43.1094 -35.9023 -85.9025 1748 
FZ419_86 470 -26.1678 -52.7501 -33.2123 -88.6007 1749 
FZ47_6 471 -22.5302 -57.4264 -31.4613 -91.5073 1768 
FZ178_155 472 -27.4095 -52.6625 -31.4853 -91.9513 1772 
FZ399_151 473 -25.4992 -50.1635 -32.8577 -89.935 1795 
FZ67_2 474 -21.499 -45.65 -36.5109 -73.4211 1798 
FZ122_32 475 -25.7122 -52.6715 -32.1852 -84.6651 1802 
FZ155_124 476 -28.3205 -46.5324 -29.472 -102.138 1807 
FZ139_139 477 -24.5988 -35.6313 -34.4862 -96.9801 1821 
FZ97_125 478 -30.9754 -42.783 -31.4795 -92.81 1822 
FZ158_139 479 -24.5988 -35.6313 -34.4862 -96.9801 1825 
FZ180_12 480 -23.8243 -37.5738 -36.1302 -72.7804 1840 
FZ259_86 481 -23.2802 -33.7651 -28.6724 -114.398 1840 
FZ284_62 482 -22.6186 -47.2 -31.6565 -96.7682 1841 
FZ501_94 483 -18.6842 -53.6811 -29.4737 -92.9293 1845 
FZ112_29 484 -30.5805 -40.4975 -31.5627 -91.633 1850 
FZ88_1 485 -31.7226 -47.0655 -28.4738 -86.5441 1850 
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FZ196_71 486 -21.3918 -46.4914 -28.7891 -104.589 1852 
FZ271_7 487 -29.2458 -30.3572 -29.2537 -106.213 1860 
FZ220_186 488 -23.4159 -30.7713 -33.2005 -100.828 1861 
FZ405_177 489 -34.4357 -29.8605 -32.7998 -74.1393 1865 
FZ300_152 490 -30.3435 -41.1029 -24.1569 -103.817 1865 
FZ545_25 491 -19.1277 -47.9433 -30.1601 -98.6303 1869 
FZ343_152 492 -30.3435 -41.1029 -24.1569 -103.817 1869 
FZ236_80 493 -22.912 -47.0839 -30.3401 -95.818 1872 
FZ277_63 494 -30.6286 -41.6657 -30.3418 -88.8158 1874 
FZ308_2 495 -23.0287 -51.1283 -31.0031 -82.5385 1874 
FZ86_11 496 -26.8238 -42.4095 -32.7629 -85.1708 1876 
FZ387_33 497 -21.3723 -52.0476 -30.8457 -80.4135 1878 
FZ296_103 498 -17.1055 -60.6637 -26.8012 -69.6969 1882 
FZ339_103 499 -17.1055 -60.6637 -26.8012 -69.6969 1884 
FZ38_81 500 -24.6501 -47.2201 -26.6136 -97.1876 1894 
FZ87_79 501 -20.1576 -31.8557 -34.1943 -91.7674 1898 
FZ69_39 502 -18.2702 -36.8643 -33.6003 -93.7077 1899 
FZ441_117 503 -13.9469 -53.9478 -25.9321 -93.2628 1900 
FZ244_71 504 -27.5175 -45.1804 -19.9053 -97.8568 1915 
FZ527_15 505 -19.435 -45.762 -32.5331 -80.7078 1921 
FZ467_66 506 -25.0082 -27.8283 -34.4992 -69.6031 1924 
FZ182_21 507 -34.2856 -39.3592 -24.5953 -79.7568 1931 
FZ234_66 508 -22.0905 -35.0688 -32.9947 -87.0834 1939 
FZ381_100 509 -24.665 -36.4613 -30.4152 -92.4078 1942 
FZ216_54 510 -29.9698 -23.0091 -31.5367 -81.8006 1949 
FZ229_57 511 -24.3778 -37.3781 -28.3272 -96.7757 1949 
FZ280_119 512 -13.5357 -49.1043 -22.5562 -97.2638 1956 
FZ242_45 513 -19.7199 -21.9025 -32.4898 -96.0584 1959 
FZ274_49 514 -24.6936 -16.4915 -31.239 -92.2562 1966 
FZ232_123 515 -22.5439 -36.7762 -27.2586 -98.5505 1967 
FZ73_2 516 -21.2503 -30.8421 -32.8064 -84.9697 1968 
FZ375_78 517 -29.6168 -46.8118 -22.0266 -72.622 1968 
FZ198_8 518 -18.1633 -39.774 -32.2415 -82.1756 1970 
FZ39_81 519 -14.9927 -52.1614 -26.6684 -63.4149 1988 
FZ37_81 520 -14.9927 -52.1614 -26.6684 -63.4149 1990 
FZ248_25 521 -7.9712 -38.0529 -30.04 -92.2688 2003 
FZ224_73 522 -20.165 -23.8228 -31.6146 -86.8725 2007 
FZ266_140 523 -10.8849 -25.2824 -27.54 -103.371 2012 
FZ357_184 524 -14.6281 -43.5498 -30.4452 -70.4016 2014 
FZ241_34 525 -6.79 -53.0992 -16.6205 -56.6215 2030 
FZ109_6 526 -11.7372 -46.0078 -28.3089 -73.8141 2032 
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FZ264_108 527 -14.05 -33.0316 -32.7658 -65.8112 2032 
FZ278_30 528 -27.9333 -24.1971 -24.0809 -87.1119 2036 
FZ217_57 529 -20.1654 -36.9792 -20.6847 -93.155 2041 
FZ230_72 530 -12.6319 -26.1485 -32.4006 -75.5063 2044 
FZ141_107 531 -17.7467 -42.4182 -27.6534 -73.5287 2045 
FZ99_73 532 -3.5744 -50.7137 -26.3127 -50.18 2046 
FZ159_107 533 -17.7467 -42.4182 -27.6534 -73.5288 2047 
FZ503_76 534 -17.6386 -12.6714 -29.951 -90.5476 2048 
FZ572_8 535 -15.7649 -30.3051 -31.0922 -78.998 2053 
FZ85_99 536 -19.7383 -29.2458 -30.2603 -72.1816 2066 
FZ210_17 537 -6.6913 -44.8938 -25.5962 -80.1002 2068 
FZ228_75 538 -22.272 -19.4072 -29.6353 -73.5714 2068 
FZ359_141 539 -18.6487 -29.8224 -28.399 -80.7928 2072 
FZ395_59 540 -12.4824 -37.2107 -30.2284 -59.4375 2073 
FZ121_27 541 -12.3243 -39.99 -26.4031 -80.3355 2081 
FZ371_97 542 -4.8427 -45.3257 -26.735 -56.8396 2085 
FZ246_7 543 -11.2734 -41.2011 -21.3921 -84.1058 2090 
FZ443_78 544 2.5388 -48.1488 -21.5059 -49.6692 2096 
FZ53 545 2.8121 -46.9778 -23.0059 -56.0433 2098 
FZ192_40 546 -17.7954 -24.5921 -27.504 -77.0325 2108 
FZ204_90 547 -12.4338 -23.1862 -28.7417 -77.5642 2112 
FZ240_2 548 -12.4411 -21.0854 -28.5603 -79.1328 2113 
FZ54_8 549 13.4665 -45.9557 -25.4055 -43.9675 2115 
FZ42_25 550 0.0071 -41.0787 -27.7095 -37.1522 2123 
FZ407_64 551 -17.5384 -34.7329 -21.009 -75.5743 2129 
FZ153_90 552 -4.8267 -44.4343 -21.2669 -40.6413 2130 
FZ292_25 553 -3.4152 -35.3264 -23.893 -77.7538 2144 
FZ383_104 554 -7.0944 -34.686 -26.0843 -64.1516 2146 
FZ262_21 555 -12.0473 -27.9951 -22.2009 -79.3365 2149 
FZ52_8 556 -12.0031 -27.823 -27.4021 -52.6416 2152 
FZ260_107 557 -1.2291 -41.4326 -17.9254 -47.3465 2160 
FZ298_79 558 -3.778 -36.5102 -24.9363 -49.6273 2161 
FZ341_79 559 -3.778 -36.5102 -24.9363 -49.6273 2163 
FZ206_89 560 -1.2592 -37.7996 -19.195 -52.3302 2168 
FZ218_81 561 2.8746 -38.1175 -14.6371 -48.0451 2179 
FZ272_82 562 -0.2856 -37.0467 -12.2068 -53.0586 2180 
FZ258_51 563 9.4193 -23.7001 -18.132 -38.2578 2230 
FZ270_75 564 43.1607 -14.6264 -5.9986 -1.2922 2247 
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FZ229_57 565 -24.3778 -37.3781 -28.3272 -96.7757 1949 
FZ280_119 567 -13.5357 -49.1043 -22.5562 -97.2638 1956 
FZ242_45 568 -19.7199 -21.9025 -32.4898 -96.0584 1959 
FZ274_49 569 -24.6936 -16.4915 -31.239 -92.2562 1966 
FZ232_123 600 -22.5439 -36.7762 -27.2586 -98.5505 1967 
FZ73_2 601 -21.2503 -30.8421 -32.8064 -84.9697 1968 
FZ375_78 602 -29.6168 -46.8118 -22.0266 -72.622 1968 
FZ198_8 603 -18.1633 -39.774 -32.2415 -82.1756 1970 
FZ39_81 604 -14.9927 -52.1614 -26.6684 -63.4149 1988 
FZ37_81 605 -14.9927 -52.1614 -26.6684 -63.4149 1990 
FZ248_25 606 -7.9712 -38.0529 -30.04 -92.2688 2003 
FZ224_73 607 -20.165 -23.8228 -31.6146 -86.8725 2007 
FZ266_140 608 -10.8849 -25.2824 -27.54 -103.371 2012 
FZ357_184 609 -14.6281 -43.5498 -30.4452 -70.4016 2014 
FZ241_34 610 -6.79 -53.0992 -16.6205 -56.6215 2030 
FZ109_6 611 -11.7372 -46.0078 -28.3089 -73.8141 2032 
FZ264_108 612 -14.05 -33.0316 -32.7658 -65.8112 2032 
FZ278_30 613 -27.9333 -24.1971 -24.0809 -87.1119 2036 
FZ217_57 614 -20.1654 -36.9792 -20.6847 -93.155 2041 
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FZ230_72 615 -12.6319 -26.1485 -32.4006 -75.5063 2044 
FZ141_107 616 -17.7467 -42.4182 -27.6534 -73.5287 2045 
FZ99_73 617 -3.5744 -50.7137 -26.3127 -50.18 2046 
FZ159_107 618 -17.7467 -42.4182 -27.6534 -73.5288 2047 
FZ503_76 619 -17.6386 -12.6714 -29.951 -90.5476 2048 
FZ572_8 620 -15.7649 -30.3051 -31.0922 -78.998 2053 
FZ85_99 621 -19.7383 -29.2458 -30.2603 -72.1816 2066 
FZ210_17 622 -6.6913 -44.8938 -25.5962 -80.1002 2068 
FZ228_75 623 -22.272 -19.4072 -29.6353 -73.5714 2068 
FZ359_141 624 -18.6487 -29.8224 -28.399 -80.7928 2072 
FZ395_59 625 -12.4824 -37.2107 -30.2284 -59.4375 2073 
FZ121_27 626 -12.3243 -39.99 -26.4031 -80.3355 2081 
FZ371_97 627 -4.8427 -45.3257 -26.735 -56.8396 2085 
FZ246_7 628 -11.2734 -41.2011 -21.3921 -84.1058 2090 
FZ443_78 629 2.5388 -48.1488 -21.5059 -49.6692 2096 
FZ53 630 2.8121 -46.9778 -23.0059 -56.0433 2098 
FZ192_40 631 -17.7954 -24.5921 -27.504 -77.0325 2108 
FZ204_90 632 -12.4338 -23.1862 -28.7417 -77.5642 2112 
FZ240_2 633 -12.4411 -21.0854 -28.5603 -79.1328 2113 
FZ54_8 634 13.4665 -45.9557 -25.4055 -43.9675 2115 
FZ42_25 635 0.0071 -41.0787 -27.7095 -37.1522 2123 
FZ407_64 636 -17.5384 -34.7329 -21.009 -75.5743 2129 
FZ153_90 637 -4.8267 -44.4343 -21.2669 -40.6413 2130 
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FZ292_25 638 -3.4152 -35.3264 -23.893 -77.7538 2144 
FZ383_104 639 -7.0944 -34.686 -26.0843 -64.1516 2146 
FZ262_21 789 -12.0473 -27.9951 -22.2009 -79.3365 2149 
FZ52_8 791 -12.0031 -27.823 -27.4021 -52.6416 2152 
FZ260_107 792 -1.2291 -41.4326 -17.9254 -47.3465 2160 
FZ298_79 793 -3.778 -36.5102 -24.9363 -49.6273 2161 
FZ341_79 794 -3.778 -36.5102 -24.9363 -49.6273 2163 
FZ206_89 795 -1.2592 -37.7996 -19.195 -52.3302 2168 
FZ218_81 796 2.8746 -38.1175 -14.6371 -48.0451 2179 
FZ272_82 798 -0.2856 -37.0467 -12.2068 -53.0586 2180 
FZ258_51 799 9.4193 -23.7001 -18.132 -38.2578 2230 
FZ270_75 800 43.1607 -14.6264 -5.9986 -1.2922 2247 
  
 
 
 
 
 
 
 
 
